Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Ophthalmology›Condition·Updated Jun 27, 2026·v1

Diabetic Retinopathy

Diabetic retinopathy is a progressive microvascular complication of diabetes affecting ~103 million people globally, driven by hyperglycemia-induced metabolic injury, inflammation, and retinal ischemia. It progresses from nonproliferative stages (NPDR) to vision-threatening proliferative DR (PDR) and diabetic macular edema (DME). Annual dilated eye exams and aggressive systemic risk factor control (HbA1c <7%, BP <130/80, fenofibrate) are the foundation of prevention. For center-involved DME and PDR, intravitreal anti-VEGF therapy (aflibercept, ranibizumab, bevacizumab, or faricimab) is first-line, with PRP reserved for cases where anti-VEGF is impractical. Vitrectomy is indicated for non-clearing vitreous hemorrhage or tractional retinal detachment. Key controversies include the role of proactive anti-VEGF in severe NPDR and the use of semaglutide in active PDR.

High Evidence479 references·2,211 words·9 min read·v1
diabetic retinopathydiabetic macular edemaanti-VEGFpanretinal photocoagulationvitrectomyscreeningfenofibrateneovascular glaucomaDRILICDR scale

Quick Reference

RxDrug of choiceAflibercept 2 mg intravitreal for CI-DME with severe vision loss (≤20/80) or first-line for PDR with VH
AltAlternativesRanibizumab 0.5 mg, bevacizumab 1.25 mg (off-label), faricimab 6 mg (bispecific anti-VEGF/Ang-2, up to q16w), dexamethasone intravitreal implant (Ozurdex 0.7 mg) for persistent DME
⊘AvoidAspirin for DR prevention (no benefit, increased bleeding); rapid glycemic improvement in active PDR (risk of early worsening); semaglutide in active PDR without monitoring
DxTest of choiceSpectral-domain optical coherence tomography (OCT) for diagnosing and monitoring diabetic macular edema; central subfield thickness ≥325 μm defines center-involved DME
ScKey scoreInternational Clinical Diabetic Retinopathy Severity Scale (ICDR), severe NPDR defined by the 4-2-1 rule (>20 hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant)
→When to referAcute vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma, or persistent DME not responding to initial anti-VEGF therapy, refer to a retina specialist within 24 hours
Diabetic retinopathy is a leading cause of preventable blindness. Early detection through annual screening, aggressive systemic risk factor control (HbA1c <7%, BP <130/80, fenofibrate), and timely anti-VEGF therapy for vision-threatening disease can dramatically reduce progression and vision loss.
Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus leading to retinal capillary damage, leakage, ischemia, and neovascularization, and remains a leading cause of preventable blindness in working-age adults globally [7, 21]. It affects approximately one-third of the 537 million adults with diabetes, and its prevalence rises with diabetes duration and poor glycemic control [7, 21].

Overview and Recommendations

Background

  • •Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus, characterized by retinal capillary damage leading to vascular leakage, ischemia, and neovascularization. It affects approximately 103 million people globally, about 22% of all individuals with diabetes, and remains a leading cause of preventable blindness among working-age adults (20-74 years) in high-income countries.
  • •Chronic hyperglycemia drives four interconnected metabolic pathways, the polyol pathway, advanced glycation end products (AGEs) formation, protein kinase C (PKC) activation, and hexosamine pathway flux, that converge on mitochondrial overproduction of superoxide, generating oxidative stress and cellular injury. These pathways disrupt the neurovascular unit, with photoreceptor loss and pericyte death preceding clinically visible vasculopathy by months to years.
  • •Retinal ischemia stabilizes hypoxia-inducible factor-1α (HIF-1α), which transcriptionally upregulates vascular endothelial growth factor (VEGF), the master driver of pathological angiogenesis, leading to neovascularization of the disc (NVD) or elsewhere (NVE), vitreous hemorrhage, and tractional retinal detachment in proliferative DR (PDR).
  • •Two complementary classification systems guide clinical staging: the simplified International Clinical Diabetic Retinopathy (ICDR) scale, which categorizes severity as no DR, mild/moderate/severe NPDR, and PDR, and the more detailed Early Treatment Diabetic Retinopathy Study (ETDRS) scale (levels 10-85). Diabetic macular edema (DME) is classified separately based on optical coherence tomography as center-involved (CI-DME) or non-center-involved DME. Vision-threatening DR (VTDR) encompasses severe NPDR, PDR, and CI-DME and is the primary target for screening and intervention.

Evaluation

  • •Suspect diabetic retinopathy in any patient with diabetes, especially those with longer disease duration (>10 years), poor glycemic control (HbA1c > 7%), or concurrent hypertension. Most patients are asymptomatic until vision-threatening complications develop.
  • •Ask about recent visual symptoms: blurring, metamorphopsia, difficulty reading or recognizing faces (suggesting DME), or sudden floaters, flashes, or curtain-like vision loss (suggesting vitreous hemorrhage or retinal detachment). Note any history of prior laser, anti-VEGF injections, or vitrectomy.
  • •Examine visual acuity (best corrected) and perform a dilated fundus examination with slit-lamp biomicroscopy (78D or 90D lens). Look for microaneurysms, dot-and-blot hemorrhages, hard exudates, cotton-wool spots (NPDR), and neovascularization of the disc (NVD) or elsewhere (NVE), vitreous hemorrhage, or tractional retinal detachment (PDR). Examine the iris for rubeosis (neovascularization) suggesting neovascular glaucoma.
  • •Grade severity using the ICDR scale: no DR → no abnormalities; mild NPDR → microaneurysms only; moderate NPDR → more than microaneurysms but less than severe; severe NPDR → any of the 4-2-1 rule (>20 intraretinal hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant); PDR → neovascularization or vitreous/preretinal hemorrhage.
  • •Order spectral-domain optical coherence tomography (OCT) to assess for DME. Center-involved DME is defined by central subfield thickness (CST) ≥ 325 μm on spectral-domain OCT. Evaluate for qualitative biomarkers: disorganization of retinal inner layers (DRIL) predicts poor visual response to anti-VEGF therapy; hyperreflective foci, subretinal fluid, and ellipsoid zone disruption correlate with worse outcomes.
  • •If neovascularization is suspected or vision loss persists despite normal OCT, perform fluorescein angiography (FA) to detect retinal NV and capillary nonperfusion. Ultra-widefield FA captures peripheral ischemia beyond standard ETDRS fields and predicts progression risk. OCT angiography is a noninvasive alternative that visualizes capillary dropout and can distinguish active NV from quiescent fibrovascular proliferation.
  • •Assess systemic risk factors: measure HbA1c, blood pressure, serum lipids (especially LDL), and renal function (eGFR, urine albumin-to-creatinine ratio). Evaluate for obstructive sleep apnea, which independently increases DR risk (OR 1.45, 95% CI 1.20-1.75).
  • •In screening settings, use AI-based fundus photography (e.g., EyeArt, IDx-DR) as a triage tool to identify patients requiring specialist referral. AI systems achieve pooled sensitivity of 87-96% and specificity of 86-93% for referable DR (moderate NPDR or worse).
  • •Consider functional testing (multifocal ERG, microperimetry) in research settings or for unexplained visual complaints with minimal fundus findings; these reveal neuroretinal dysfunction before structural changes appear.
  • •Red flags requiring same-day referral to a retina specialist: sudden vision loss with floaters (acute vitreous hemorrhage from PDR), pain with elevated IOP and rubeosis (neovascular glaucoma), or progressive visual field loss suggesting tractional retinal detachment.

Management

  • •Initiate intensive systemic risk factor control as the foundation of DR management: target HbA1c <7% (or <6.5% in selected patients without hypoglycemia risk), blood pressure <130/80 mmHg, and LDL <100 mg/dL. The J-DOIT3 trial showed that such multifactorial intervention reduces retinopathy progression by 40% (HR 0.60, 95% CI 0.44-0.82).
  • •Consider fenofibrate (145 mg daily) as adjunctive systemic therapy to slow DR progression, especially in patients with early NPDR and dyslipidemia. The LENS trial demonstrated a 27% relative risk reduction in progression (HR 0.73, 95% CI 0.58-0.91; NNT = 16 over 4 years).
  • •For center-involved DME with vision loss, administer intravitreal anti-VEGF therapy as first-line treatment. Aflibercept 2 mg (5 monthly loading doses, then 2 mg every 8 weeks) is preferred for severe vision loss (≤20/80) based on DRCR.net Protocol T (mean gain +10.7 letters at 1 year). Alternatives: ranibizumab 0.5 mg (monthly ×3-5, then treat-and-extend) or bevacizumab 1.25 mg (off-label, monthly PRN). Faricimab 6 mg (bispecific anti-VEGF/anti-Ang-2) is noninferior to aflibercept and allows up to 16-week dosing intervals.
  • •For persistent DME despite anti-VEGF, consider dexamethasone intravitreal implant (0.7 mg, Ozurdex); the MEAD study showed 22% of treated eyes gained ≥15 letters vs 12% with sham (OR 2.1, P=0.016). Monitor for cataract and elevated IOP.
  • •For proliferative DR with vitreous hemorrhage or high-risk characteristics, administer intravitreal anti-VEGF as first-line therapy (aflibercept 2 mg monthly ×3 then q8w, or ranibizumab 0.5 mg monthly until regression). A meta-analysis of 5 RCTs confirmed anti-VEGF reduces vitrectomy need by 40% (RR 0.60, 95% CI 0.44-0.82; NNT = 12).
  • •Perform panretinal photocoagulation (PRP) if anti-VEGF is contraindicated, inaccessible, or if follow-up is uncertain. Deliver 1200-1600 burns (500 μm spot size, argon or frequency-doubled Nd:YAG 532 nm) in 2-4 sessions using pattern-scanning laser (PASCAL) to reduce pain. The ETDRS established that PRP reduces severe vision loss by 50% (from 26% to 13%).
  • •For severe NPDR without DME, consider proactive anti-VEGF therapy (e.g., aflibercept 2 mg q8w after 5 monthly doses) in high-risk patients (poor glycemic control, prior PDR in fellow eye). The PANORAMA trial showed this reduces 2-year progression to PDR or CI-DME from 43% to 16% (HR 0.32; NNT = 4).
  • •If vitreous hemorrhage does not clear within 4-6 weeks after anti-VEGF, or if tractional retinal detachment involves the fovea, perform pars plana vitrectomy (PPV). Administer preoperative intravitreal bevacizumab 1.25 mg 3-7 days before surgery to reduce intraoperative bleeding (RR 0.38, 95% CI 0.24-0.60) and shorten surgical time by ~27 minutes. Endolaser photocoagulation is applied to ischemic retina during surgery.
  • •For neovascular glaucoma (rubeosis with IOP >30 mmHg), emergently lower IOP with topical beta-blockers, alpha-agonists, and oral acetazolamide (500 mg IV or PO). Administer intravitreal bevacizumab 1.25 mg to regress iris NV within 48-72 hours, followed by PRP once media clears. If IOP remains >30 mmHg despite maximal therapy, place a glaucoma drainage implant (e.g., Ahmed valve).
  • •After initial treatment, monitor patients monthly using a treat-and-extend protocol (extend intervals by 2 weeks per visit, up to a maximum of 12-16 weeks) based on disease activity on OCT and clinical exam.
  • •Do NOT use aspirin for DR prevention or progression; the ASCEND-Eye trial (N=15,480) showed no benefit (HR 1.02, 95% CI 0.92-1.13) and increased gastrointestinal bleeding risk.
  • •Do NOT initiate rapid glycemic improvement in patients with active PDR or severe NPDR; the ACCORD Eye study found a 40% increased risk of early DR worsening (NNT = 25 for harm). Gradually lower HbA1c by <1% per month.
  • •Do NOT use semaglutide in patients with active PDR without careful monitoring; the SUSTAIN-6 trial reported a 76% increased risk of DR complications (HR 1.76, 95% CI 1.11-2.78).
  • •Refer to a retina specialist within 24 hours for: acute vitreous hemorrhage obscuring the macula, tractional retinal detachment involving/fovea-threatening, neovascular glaucoma, or severe vision loss due to DME not responding to initial therapy.

Board Review — High Yield

  • •Metabolic memory, Prior glycemic control continues to influence retinopathy risk years later via epigenetic modifications (DNA methylation, histone acetylation, microRNA dysregulation); the DCCT/EDIC study demonstrated this phenomenon.
  • •4-2-1 rule for severe NPDR, Intraretinal hemorrhages in 4 quadrants, venous beading in 2 quadrants, or IRMA in 1 quadrant; this defines severe nonproliferative DR and carries a 13.5% 2-year risk of progression to PDR.
  • •VEGF axis, Hypoxia stabilizes HIF-1α, which transcriptionally upregulates VEGF-A (master driver of pathological angiogenesis). Anti-VEGF therapy (aflibercept, ranibizumab, bevacizumab) targets this pathway and is the standard of care for CI-DME and PDR.
  • •DRIL, Disorganization of retinal inner layers on OCT is a strong negative prognostic biomarker for visual outcomes after anti-VEGF therapy for DME (OR 2.8 for poor response).
  • •PANORAMA trial, Proactive aflibercept 2 mg every 8 weeks in severe NPDR reduced 2-year progression to PDR or CI-DME from 43% to 16% (NNT = 4), supporting early intervention in high-risk patients.
  • •Preoperative anti-VEGF before vitrectomy, Intravitreal bevacizumab 1.25 mg given 3-7 days before PPV reduces intraoperative bleeding (RR 0.38), shortens surgical time by 27 minutes, and decreases recurrent VH (RR 0.37).
  • •Neovascular glaucoma emergency, Rubeosis iridis with IOP >30 mmHg requires immediate IOP reduction (beta-blockers + acetazolamide), urgent intravitreal anti-VEGF, and PRP once media clears; if refractory, glaucoma drainage implant.
  • •ASCEND-Eye trial, Aspirin 100 mg daily showed no benefit for DR prevention or progression (HR 1.02, 95% CI 0.92-1.13) and increased bleeding risk, do not use for DR.
  • •Fenofibrate, The LENS trial demonstrated that fenofibrate 145 mg daily reduces DR progression by 27% (HR 0.73; NNT = 16 over 4 years), positioning it as an adjunctive systemic therapy for early DR and dyslipidemia.
  • •Semaglutide caution, SUSTAIN-6 trial found a 76% increased risk of DR complications with semaglutide (HR 1.76, 95% CI 1.11-2.78); use with caution in patients with active PDR.

Deep Dive — Evidence Details

References

  1. [1]

    Sammons EL, Buck G, Bowman LJ et al.. “ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.” Ophthalmology (2024). PMID: 38237868 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  2. [2]

    Sammons EL, Buck G, Bowman LJ et al.. “ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.” Ophthalmology (2023). PMID: 38052385 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  3. [3]

    Aiello LP, Blodi B, Gao X et al.. “Ultra-Widefield and Early Treatment Diabetic Retinopathy Study 7-Field Grading of Diabetic Retinopathy.” JAMA ophthalmology (2024). PMID: 39145984 ↗

    L2RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  4. [4]

    Fu DJ, Bagga P, Naik G et al.. “Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.” JAMA ophthalmology (2024). PMID: 38722644 ↗

    L2RCTCited in: Definition, Classification & Nomenclature
  5. [5]

    Nanji K, Grad J, Hatamnejad A et al.. “Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis.” Ophthalmology (2025). PMID: 40803536 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  6. [6]

    Solomon SD, Shoge RY, Ervin AM et al.. “Improving Access to Eye Care: A Systematic Review of the Literature.” Ophthalmology (2022). PMID: 36058739 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature
  7. [7]

    Yu CW, Nanji K, Garg A et al.. “The Prevalence of Diabetic Retinopathy in American Indians or Alaska Natives and Non-Indigenous Americans: A Systematic Review and Meta-Analysis.” Ophthalmology (2025). PMID: 40816608 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  8. [8]

    Xie J, Ikram MK, Cotch MF et al.. “Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis.” JAMA ophthalmology (2017). PMID: 28472362 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
  9. [9]

    Joseph S, Wang Y, Drinkwater JJ et al.. “Effectiveness of artificial intelligence-based diabetic retinopathy screening in primary care and endocrinology settings in Australia: a pragmatic trial.” The British journal of ophthalmology (2025). PMID: 40846450 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  10. [10]

    Arruda MP, Lima RV, Hira S et al.. “A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation.” American journal of ophthalmology (2024). PMID: 38942228 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  11. [11]

    Taylor-Phillips S, Mistry H, Leslie R et al.. “Extending the diabetic retinopathy screening interval beyond 1 year: systematic review.” The British journal of ophthalmology (2015). PMID: 25586713 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  12. [12]

    Singh SR, Goté JT, Chhablani J. “Randomized controlled trials in central serous chorioretinopathy: A review.” Eye (London, England) (2023). PMID: 36997794 ↗

    L5RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  13. [13]

    Suganya Devi K, Vasireddi HK, Reddy GR et al.. “Unfolding the diagnostic pipeline of diabetic retinopathy with artificial intelligence: A systematic review.” Survey of ophthalmology (2025). PMID: 40972797 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature
  14. [14]

    Kirthi V, Nderitu P, Alam U et al.. “The prevalence of retinopathy in prediabetes: A systematic review.” Survey of ophthalmology (2022). PMID: 35430245 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
  15. [15]

    Farahat Z, Zrira N, Souissi N et al.. “Diabetic retinopathy screening through artificial intelligence algorithms: A systematic review.” Survey of ophthalmology (2024). PMID: 38885761 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  16. [16]

    Sala-Vila A, Vinagre I, Cofán M et al.. “Blood omega-3 biomarkers, diabetic retinopathy and retinal vessel status in patients with type 1 diabetes.” Eye (London, England) (2025). PMID: 39966603 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification
  17. [17]

    Tang Z, Yang D, Nguyen TX et al.. “Relationship of OCT-Based Diabetic Retinal Neurodegeneration to the Development and Progression of Diabetic Retinopathy: A Cohort Study.” Investigative ophthalmology & visual science (2025). PMID: 39932471 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
  18. [18]

    Yang S, Liu R, Xin Z et al.. “Plasma Metabolomics Identifies Key Metabolites and Improves Prediction of Diabetic Retinopathy: Development and Validation across Multinational Cohorts.” Ophthalmology (2024). PMID: 38972358 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  19. [19]

    Mohan N, Srivastava SK, Schulgit MJ et al.. “Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis.” JAMA ophthalmology (2025). PMID: 40875223 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  20. [20]

    Jindal DA, Hanna J, Shaia JK et al.. “Metformin and the Development of Age-Related Macular Degeneration.” JAMA ophthalmology (2025). PMID: 40965862 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  21. [21]

    Markle J, Shaia JK, Araich H et al.. “Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network.” JAMA ophthalmology (2024). PMID: 38869883 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  22. [22]

    Szeto SK, Lai TY, Vujosevic S et al.. “Optical coherence tomography in the management of diabetic macular oedema.” Progress in retinal and eye research (2023). PMID: 37944588 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  23. [23]

    Ng DSC, Ruamviboonsuk P, Apte RS et al.. “International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME).” Progress in retinal and eye research (2025). PMID: 41005472 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations, Screening & Prevention
  24. [24]

    Sampani K, Fickweiler W, Markel DS et al.. “Diabetic retinal disease cure accelerator: Modernizing staging and endpoints.” Progress in retinal and eye research (2026). PMID: 42173402 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  25. [25]

    Schmidt-Erfurth U, Sadeghipour A, Gerendas BS et al.. “Artificial intelligence in retina.” Progress in retinal and eye research (2018). PMID: 30076935 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
  26. [26]

    Cheung CMG, Fawzi A, Teo KY et al.. “Diabetic macular ischaemia- a new therapeutic target?” Progress in retinal and eye research (2021). PMID: 34902545 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Prognosis & Natural History
  27. [27]

    Stefánsson E, Olafsdottir OB, Eliasdottir TS et al.. “Retinal oximetry: Metabolic imaging for diseases of the retina and brain.” Progress in retinal and eye research (2019). PMID: 30999027 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation
  28. [28]

    Lopes de Jesus CC, Atallah AN, Valente O et al.. “Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy.” The Cochrane database of systematic reviews (2008). PMID: 18254110 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
  29. [29]

    Jorge EC, Jorge EN, Botelho M et al.. “Monotherapy laser photocoagulation for diabetic macular oedema.” The Cochrane database of systematic reviews (2018). PMID: 30320466 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  30. [30]

    Virgili G, Menchini F, Murro V et al.. “Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.” The Cochrane database of systematic reviews (2011). PMID: 21735421 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
  31. [31]

    Wai KM, Mishra K, Koo E et al.. “Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.” American journal of ophthalmology (2024). PMID: 38636788 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  32. [32]

    Lee CS, Krakauer C, Su YR et al.. “Diabetic Retinopathy and Dementia Association, Beyond Diabetes Severity.” American journal of ophthalmology (2022). PMID: 36513155 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  33. [33]

    Browning DJ, Yokogawa N, Greenberg PB et al.. “Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.” American journal of ophthalmology (2020). PMID: 32610049 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  34. [34]

    Liang F, Tao S, Zhang Y et al.. “Correlation Between Length of Interdigitation Zone With Severity and Progression of Diabetic Retinopathy.” American journal of ophthalmology (2025). PMID: 40157446 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  35. [35]

    Ramirez M, Kitayama K, Puran A et al.. “The Associations Between Glaucoma and Circadian Rhythm Sleep Disorders in California Medicare Beneficiaries.” American journal of ophthalmology (2025). PMID: 40545017 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  36. [36]

    Ting DSW, Pasquale LR, Peng L et al.. “Artificial intelligence and deep learning in ophthalmology.” The British journal of ophthalmology (2018). PMID: 30361278 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Special Populations, Screening & Prevention
  37. [37]

    Whitestone N, Nkurikiye J, Patnaik JL et al.. “Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda.” The British journal of ophthalmology (2024). PMID: 37541766 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
  38. [38]

    Wu H, Su Z, Pan X et al.. “Enhancing diabetic retinopathy query responses: assessing large language model in ophthalmology.” The British journal of ophthalmology (2025). PMID: 40588331 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
  39. [39]

    Fleming AD, Mellor J, McGurnaghan SJ et al.. “Deep learning detection of diabetic retinopathy in Scotland's diabetic eye screening programme.” The British journal of ophthalmology (2024). PMID: 37704266 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
  40. [40]

    Preiss D, Logue J, Sammons E et al.. “Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial.” Health technology assessment (Winchester, England) (2026). PMID: 42117585 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Prognosis & Natural History
  41. [41]

    Sorour OA, Levine ES, Baumal CR et al.. “Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods.” Survey of ophthalmology (2022). PMID: 36436614 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  42. [42]

    Kiire CA, Porta M, Chong V. “Medical management for the prevention and treatment of diabetic macular edema.” Survey of ophthalmology (2013). PMID: 23969020 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  43. [43]

    Vaughan N. “Review of smartphone funduscopy for diabetic retinopathy screening.” Survey of ophthalmology (2023). PMID: 37806567 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  44. [44]

    Curcio CA, Kar D, Owsley C et al.. “Age-Related Macular Degeneration, a Mathematically Tractable Disease.” Investigative ophthalmology & visual science (2024). PMID: 38466281 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation
  45. [45]

    Wang W, Liu S, Qiu Z et al.. “Choroidal Thickness in Diabetes and Diabetic Retinopathy: A Swept Source OCT Study.” Investigative ophthalmology & visual science (2020). PMID: 32324858 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  46. [46]

    Abtahi M, Le D, Ebrahimi B et al.. “Differential Capillary and Large Vessel Analysis Improves OCTA Classification of Diabetic Retinopathy.” Investigative ophthalmology & visual science (2024). PMID: 39133470 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  47. [47]

    Sandhu HS, Eltanboly A, Shalaby A et al.. “Automated Diagnosis and Grading of Diabetic Retinopathy Using Optical Coherence Tomography.” Investigative ophthalmology & visual science (2018). PMID: 30029278 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
  48. [48]

    Gao M, Guo Y, Hormel TT et al.. “Nonperfused Retinal Capillaries-A New Method Developed on OCT and OCTA.” Investigative ophthalmology & visual science (2025). PMID: 40202734 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  49. [49]

    Popovic MM, Feo A, Sadda SR et al.. “Large Retinal Capillary Aneurysm: A Delphi Consensus Study and Updated Nomenclature for a Signature Optical Coherence Tomography Lesion.” Retina (Philadelphia, Pa.) (2025). PMID: 40456130 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  50. [50]

    Yassin SH, Wagner NE, Kalaw FGP et al.. “RETINAL VESSELS WHITENING IN RETINITIS PIGMENTOSA.” Retina (Philadelphia, Pa.) (2025). PMID: 40262144 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
  51. [51]

    Castellanos-Canales D, Decker NL, Fukuyama H et al.. “RELIABILITY OF CLINICAL GRADING OF DIABETIC RETINOPATHY COMPARED WITH GRADING OF ULTRA-WIDEFIELD IMAGES.” Retina (Philadelphia, Pa.) (2024). PMID: 39047122 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
  52. [52]

    Le D, Dadzie A, Son T et al.. “COMPARATIVE ANALYSIS OF OCT AND OCT ANGIOGRAPHY CHARACTERISTICS IN EARLY DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2023). PMID: 36763982 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  53. [53]

    Romano F, Cozzi M, Monteduro D et al.. “NATURAL COURSE AND CLASSIFICATION OF EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN-LIKE APPEARANCE.” Retina (Philadelphia, Pa.) (2023). PMID: 36727827 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  54. [54]

    Kim K, Kim ES, Yu SY. “PREDICTION OF DIABETIC RETINOPATHY SEVERITY USING A COMBINATION OF RETINAL NEURODEGENERATION AND CAPILLARY NONPERFUSION ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.” Retina (Philadelphia, Pa.) (2023). PMID: 37116460 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
  55. [55]

    Abdelaal A, Mahmoud YA, Alsouri W et al.. “Bidirectional association between obstructive sleep apnea and diabetic retinopathy: a severity-stratified systematic review and meta-analysis with GRADE assessment.” Acta diabetologica (2026). PMID: 42334598 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
  56. [56]

    Chen KY, Chan HC, Chan CM. “Association between omega-6 fatty acids and diabetic retinopathy risk: a systematic review and meta-analysis.” Nutrition & diabetes (2026). PMID: 42276994 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  57. [57]

    Yang X, Guo J, Wei T et al.. “Quantifying the evidence on associated factors for diabetes-related foot complications: An umbrella review of published systematic reviews and meta-analyses.” Diabetes research and clinical practice (2026). PMID: 42251949 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  58. [58]

    Chen KY, Chan HC, Chan CM. “Clinical setting-dependent diagnostic accuracy of artificial intelligence and store-and-forward diabetic retinopathy screening: a systematic review and meta-analysis.” NPJ digital medicine (2026). PMID: 42141103 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  59. [59]

    Wu Z, Li L. “Effectiveness of screening modalities for early detection of diabetic retinopathy: a systematic review and meta-analysis of tele-ophthalmology, AI-based tools, and conventional methods.” Frontiers in medicine (2026). PMID: 42100279 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  60. [60]

    Cunha-Vaz J, Mendes L, Reste-Ferreira D. “Understanding nonproliferative diabetic retinopathy progression using noninvasive imaging.” Eye (London, England) (2025). PMID: 40646245 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
  61. [61]

    Amoaku WM, Ghanchi F, Bailey C et al.. “Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.” Eye (London, England) (2020). PMID: 32504038 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  62. [62]

    Menean M, Sacconi R, Tombolini B et al.. “Combined wide-field imaging in grading diabetic retinopathy.” Eye (London, England) (2023). PMID: 37524829 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  63. [63]

    Das T, Takkar B, Sivaprasad S et al.. “Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities.” Eye (London, England) (2021). PMID: 33976399 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Special Populations, Screening & Prevention
  64. [64]

    Staurenghi G, Ye L, Magee MH et al.. “Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.” Ophthalmology (2015). PMID: 25749297 ↗

    L1RCTCited in: Pathophysiology & Mechanism
  65. [65]

    Scott IU, Jackson GR, Quillen DA et al.. “Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.” JAMA ophthalmology (2014). PMID: 24604308 ↗

    L1RCTCited in: Pathophysiology & Mechanism
  66. [66]

    Schoenberger SD, Kim SJ, Shah R et al.. “Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy.” JAMA ophthalmology (2014). PMID: 24336915 ↗

    L1RCTCited in: Pathophysiology & Mechanism
  67. [67]

    Sala-Vila A, Díaz-López A, Valls-Pedret C et al.. “Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial.” JAMA ophthalmology (2016). PMID: 27541690 ↗

    L2RCTCited in: Pathophysiology & Mechanism
  68. [68]

    Staurenghi G, Feltgen N, Arnold JJ et al.. “Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.” The British journal of ophthalmology (2017). PMID: 29051325 ↗

    L2RCTCited in: Pathophysiology & Mechanism
  69. [69]

    Huang Y, Zhang N, Bulloch G et al.. “Rates of Choroidal and Neurodegenerative Changes Over Time in Diabetic Patients Without Retinopathy: A 3-Year Prospective Study.” American journal of ophthalmology (2022). PMID: 35870490 ↗

    L2COHORTCited in: Pathophysiology & Mechanism
  70. [70]

    Zhang S, Zhu Z, Bulloch G et al.. “PROGRESSIVE PERIPAPILLARY CHOROID THINNING AND RETINAL NEURODEGENERATION IN PATIENTS WITH DIABETES: A 3-Year Cohort Study.” Retina (Philadelphia, Pa.) (2022). PMID: 36394894 ↗

    L2COHORTCited in: Pathophysiology & Mechanism
  71. [71]

    Puech B, Lacour A, Stevanin G et al.. “Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene.” Ophthalmology (2010). PMID: 21035867 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism
  72. [72]

    Das A, McGuire PG, Rangasamy S. “Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.” Ophthalmology (2015). PMID: 25935789 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  73. [73]

    Miller JW, Le Couter J, Strauss EC et al.. “Vascular endothelial growth factor a in intraocular vascular disease.” Ophthalmology (2012). PMID: 23031671 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  74. [74]

    Chong YH, Fan Q, Tham YC et al.. “Type 2 Diabetes Genetic Variants and Risk of Diabetic Retinopathy.” Ophthalmology (2016). PMID: 28038984 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  75. [75]

    Raman R, Rani PK, Reddi Rachepalle S et al.. “Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2.” Ophthalmology (2008). PMID: 19084275 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  76. [76]

    Kwon SH, Shin JP, Kim IT et al.. “Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy.” Ophthalmology (2015). PMID: 25687026 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  77. [77]

    Huang YC, Lin JM, Lin HJ et al.. “Genome-wide association study of diabetic retinopathy in a Taiwanese population.” Ophthalmology (2011). PMID: 21310492 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  78. [78]

    Knol JA, van Kooij B, de Valk HW et al.. “Rapid progression of diabetic retinopathy in eyes with posterior uveitis.” American journal of ophthalmology (2006). PMID: 16458715 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism
  79. [79]

    Lee B, Novais EA, Waheed NK et al.. “En Face Doppler Optical Coherence Tomography Measurement of Total Retinal Blood Flow in Diabetic Retinopathy and Diabetic Macular Edema.” JAMA ophthalmology (2017). PMID: 28196198 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  80. [80]

    Aychoua N, de Guimarães TAC, Ponnekanti MB et al.. “Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome.” JAMA ophthalmology (2026). PMID: 41296346 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  81. [81]

    Hamilton-Perais JA, Wright DM, Lim A et al.. “Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy.” JAMA ophthalmology (2026). PMID: 41165673 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management
  82. [82]

    Stitt AW, Curtis TM, Chen M et al.. “The progress in understanding and treatment of diabetic retinopathy.” Progress in retinal and eye research (2015). PMID: 26297071 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  83. [83]

    Uemura A, Fruttiger M, D'Amore PA et al.. “VEGFR1 signaling in retinal angiogenesis and microinflammation.” Progress in retinal and eye research (2021). PMID: 33640465 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  84. [84]

    Jiménez-Loygorri JI, Benítez-Fernández R, Viedma-Poyatos Á et al.. “Mitophagy in the retina: Viewing mitochondrial homeostasis through a new lens.” Progress in retinal and eye research (2023). PMID: 37454969 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  85. [85]

    Hayreh SS. “Neovascular glaucoma.” Progress in retinal and eye research (2007). PMID: 17690002 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  86. [86]

    Arrigo A, Cremona O, Aragona E et al.. “Müller cells trophism and pathology as the next therapeutic targets for retinal diseases.” Progress in retinal and eye research (2025). PMID: 40254246 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  87. [87]

    Wu CS, Cioanca AV, Gelmi MC et al.. “The multifunctional human ocular melanocortin system.” Progress in retinal and eye research (2023). PMID: 37217094 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History
  88. [88]

    Campochiaro PA. “Molecular pathogenesis of retinal and choroidal vascular diseases.” Progress in retinal and eye research (2015). PMID: 26113211 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  89. [89]

    Virgili G, Curran K, Lucenteforte E et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.” The Cochrane database of systematic reviews (2023). PMID: 38275741 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  90. [90]

    Virgili G, Parravano M, Menchini F et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema.” The Cochrane database of systematic reviews (2014). PMID: 25342124 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  91. [91]

    Virgili G, Parravano M, Evans JR et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.” The Cochrane database of systematic reviews (2018). PMID: 30325017 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  92. [92]

    Virgili G, Parravano M, Evans JR et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 28639415 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  93. [93]

    Mitry D, Bunce C, Charteris D. “Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.” The Cochrane database of systematic reviews (2013). PMID: 23440840 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  94. [94]

    Parravano M, Menchini F, Virgili G. “Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.” The Cochrane database of systematic reviews (2009). PMID: 19821414 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  95. [95]

    Virgili G, Parravano M, Menchini F et al.. “Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.” The Cochrane database of systematic reviews (2012). PMID: 23235642 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  96. [96]

    Yeong JL, Loveman E, Colquitt JL et al.. “Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.” The Cochrane database of systematic reviews (2020). PMID: 33331670 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Special Populations, Screening & Prevention
  97. [97]

    Pattwell DM, Stappler T, Sheridan C et al.. “Fibrous membranes in diabetic retinopathy and bevacizumab.” Retina (Philadelphia, Pa.) (2010). PMID: 20616680 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism
  98. [98]

    Hafner J, Zadrazil M, Grisold A et al.. “Retinal and Corneal Neurodegeneration and Their Association with Systemic Signs of Peripheral Neuropathy in Type 2 Diabetes.” American journal of ophthalmology (2019). PMID: 31542341 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  99. [99]

    Wang JC, Laíns I, Providência J et al.. “Diabetic Choroidopathy: Choroidal Vascular Density and Volume in Diabetic Retinopathy With Swept-Source Optical Coherence Tomography.” American journal of ophthalmology (2017). PMID: 28988899 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  100. [100]

    Kim K, Yu SY, Kwak HW et al.. “Retinal Neurodegeneration Associated With Peripheral Nerve Conduction and Autonomic Nerve Function in Diabetic Patients.” American journal of ophthalmology (2016). PMID: 27381712 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  101. [101]

    Penman A, Hoadley S, Wilson JG et al.. “P-selectin Plasma Levels and Genetic Variant Associated With Diabetic Retinopathy in African Americans.” American journal of ophthalmology (2015). PMID: 25794792 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  102. [102]

    Qin YJ, Chan SO, Lin HL et al.. “Increased Expression of Growth Hormone-Releasing Hormone in Fibrinous Inflammation of Proliferative Diabetic Retinopathy.” American journal of ophthalmology (2020). PMID: 32061756 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  103. [103]

    Ma Y, Tao Y, Lu Q et al.. “Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy.” American journal of ophthalmology (2011). PMID: 21704966 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  104. [104]

    Neelam K, Goenadi CJ, Lun K et al.. “Putative protective role of lutein and zeaxanthin in diabetic retinopathy.” The British journal of ophthalmology (2017). PMID: 28232380 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  105. [105]

    Alshaikh RA, Ryan KB, Waeber C. “Sphingosine 1-phosphate, a potential target in neovascular retinal disease.” The British journal of ophthalmology (2021). PMID: 33962970 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management
  106. [106]

    Cao J, Su T, Chen S et al.. “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy.” The British journal of ophthalmology (2025). PMID: 39900481 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  107. [107]

    Simó R, Hernández C. “Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications.” The British journal of ophthalmology (2012). PMID: 22887976 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  108. [108]

    Stahl A, Krohne TU, Sapieha P et al.. “Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.” The British journal of ophthalmology (2011). PMID: 21421650 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  109. [109]

    Gupta P, Yee KM, Garcia P et al.. “Vitreoschisis in macular diseases.” The British journal of ophthalmology (2010). PMID: 20584710 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  110. [110]

    Zhang Y, Huang W, Tian Q et al.. “Network pharmacology and biochemical experiments reveal the antiapoptotic mechanism of huperzine A for treating diabetic retinopathy.” The British journal of ophthalmology (2024). PMID: 37339867 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  111. [111]

    Jiang F, Lei C, Chen Y et al.. “The complement system and diabetic retinopathy.” Survey of ophthalmology (2024). PMID: 38401574 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  112. [112]

    Safi H, Safi S, Hafezi-Moghadam A et al.. “Early detection of diabetic retinopathy.” Survey of ophthalmology (2018). PMID: 29679616 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup
  113. [113]

    Takkar B, Sheemar A, Jayasudha R et al.. “Unconventional avenues to decelerate diabetic retinopathy.” Survey of ophthalmology (2022). PMID: 35803389 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  114. [114]

    Sanfilippo PG, Hewitt AW, Hammond CJ et al.. “The heritability of ocular traits.” Survey of ophthalmology (2010). PMID: 20851442 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  115. [115]

    Rai BB, Maddess T, Nolan CJ. “Functional diabetic retinopathy: A new concept to improve management of diabetic retinal diseases.” Survey of ophthalmology (2024). PMID: 39581562 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  116. [116]

    Chychko L, Son HS, Friedrich M et al.. “The diagnostic potential of aqueous humor: Unlocking ocular and systemic insights.” Survey of ophthalmology (2025). PMID: 41419165 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  117. [117]

    Kovoor E, Chauhan SK, Hajrasouliha A. “Role of inflammatory cells in pathophysiology and management of diabetic retinopathy.” Survey of ophthalmology (2022). PMID: 35914582 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  118. [118]

    Nebbioso M, Lambiase A, Armentano M et al.. “Diabetic retinopathy, oxidative stress, and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons.” Survey of ophthalmology (2021). PMID: 33864872 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  119. [119]

    Lauwen S, de Jong EK, Lefeber DJ et al.. “Omics Biomarkers in Ophthalmology.” Investigative ophthalmology & visual science (2017). PMID: 28525563 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  120. [120]

    Li S, Sun D, Chen S et al.. “UCP2-SIRT3 Signaling Relieved Hyperglycemia-Induced Oxidative Stress and Senescence in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2024). PMID: 38175638 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Special Populations, Screening & Prevention
  121. [121]

    Stitt AW. “AGEs and diabetic retinopathy.” Investigative ophthalmology & visual science (2010). PMID: 20876889 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  122. [122]

    Liu L, Gao Y, Yao S. “Transthyretin-Regulated Diabetic Retinopathy Through the VEGFA/PI3K/AKT Pathway.” Investigative ophthalmology & visual science (2024). PMID: 38289614 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  123. [123]

    Lopes de Faria JM, Duarte DA, Montemurro C et al.. “Defective Autophagy in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2016). PMID: 27564518 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup
  124. [124]

    He Y, Zhou J, Wang J et al.. “Novel Visceral Obesity Indicators and Associated Metabolic Fingerprint in Incident Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40919861 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Special Populations, Screening & Prevention
  125. [125]

    Liu D, Meng Z, Jin C et al.. “Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis.” Investigative ophthalmology & visual science (2025). PMID: 40042877 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  126. [126]

    Vujosevic S, Simó R. “Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach.” Investigative ophthalmology & visual science (2017). PMID: 28510630 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  127. [127]

    Kirthi V, Zuckerman BP, Alam U et al.. “ASSOCIATIONS BETWEEN DYSGLYCEMIA, RETINAL NEURODEGENERATION, AND MICROALBUMINURIA IN PREDIABETES AND TYPE 2 DIABETES.” Retina (Philadelphia, Pa.) (2022). PMID: 35188489 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  128. [128]

    Hillier RJ, Ojaimi E, Wong DT et al.. “AQUEOUS HUMOR CYTOKINE LEVELS AS BIOMARKERS OF DISEASE SEVERITY IN DIABETIC MACULAR EDEMA.” Retina (Philadelphia, Pa.) (2017). PMID: 27471825 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  129. [129]

    Nassisi M, Wohlschlegel J, Liu B et al.. “DEEP PHENOTYPING AND FURTHER INSIGHTS INTO ITM2B-RELATED RETINAL DYSTROPHY.” Retina (Philadelphia, Pa.) (2021). PMID: 32826790 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  130. [130]

    Li Z, Yang F, Deng X et al.. “ASSOCIATIONS BETWEEN CHOROIDAL ALTERATIONS AND EARLY NEURODEGENERATION IN DIABETES WITHOUT DIABETIC RETINOPATHY: Insights From Ultra-Widefield Optical Coherence Tomography Angiography Imaging.” Retina (Philadelphia, Pa.) (2024). PMID: 39047123 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  131. [131]

    Taşlipinar Uzel AG, UĞurlu N, Toklu Y et al.. “RELATIONSHIP BETWEEN STAGES OF DIABETIC RETINOPATHY AND LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN AQUEOUS HUMOR AND SERUM.” Retina (Philadelphia, Pa.) (2020). PMID: 30300266 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  132. [132]

    Lin P, Zhang N, Zhang W et al.. “Comprehensive proteomic meta-analysis identifies novel proteomics alterations in proliferative diabetic retinopathy.” Experimental eye research (2026). PMID: 42208844 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  133. [133]

    Sivaprasad S, Sen S, Cunha-Vaz J. “Perspectives of diabetic retinopathy-challenges and opportunities.” Eye (London, England) (2022). PMID: 36494431 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  134. [134]

    Al-Janabi A, Lightman S, Tomkins-Netzer O. “'Statins in retinal disease'.” Eye (London, England) (2018). PMID: 29556012 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  135. [135]

    Yerramothu P, Vijay AK, Willcox MDP. “Inflammasomes, the eye and anti-inflammasome therapy.” Eye (London, England) (2017). PMID: 29171506 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  136. [136]

    Calderon GD, Juarez OH, Hernandez GE et al.. “Oxidative stress and diabetic retinopathy: development and treatment.” Eye (London, England) (2017). PMID: 28452994 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Surgical, Laser & Procedural Considerations
  137. [137]

    Sorrentino FS, Matteini S, Bonifazzi C et al.. “Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction.” Eye (London, England) (2018). PMID: 29520046 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
  138. [138]

    Hannig L, Braunger BM, Kleefeldt N et al.. “Deletion of CEACAM1 does not affect retinal and choroidal morphology or transcriptome.” Cell and tissue research (2026). PMID: 42360388 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  139. [139]

    Zhao J, Cao Y, Chai Z et al.. “Early proteomic and metabolomic signatures in diabetes associated with progression to diabetic retinopathy over 1-2 years.” Frontiers in endocrinology (2026). PMID: 42358678 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  140. [140]

    Ramos H, Simó-Servat O, Hernández C et al.. “Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.” International journal of molecular sciences (2026). PMID: 42353267 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Surgical, Laser & Procedural Considerations
  141. [141]

    Fedotkina O, Begum MC, Trinh XT et al.. “Genome-wide association and interaction analysis for proliferative retinopathy in adults with type 2 diabetes born during famine: The DOLCE study in Ukraine.” Acta ophthalmologica (2026). PMID: 42348306 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
  142. [142]

    Hou Y, Chen T, Zhou J et al.. “The Mechanism of TNF-α Combined With High Glucose in Regulating Calnexin Aggravates Endoplasmic Reticulum Stress in Endothelial Cell Injury of Diabetic Retinopathy.” Diabetes (2026). PMID: 42330304 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  143. [143]

    Wang L, Zhang C, Li N et al.. “Research Advances in Claudin-1 in the Eye.” Experimental eye research (2026). PMID: 42320872 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  144. [144]

    Liu C, Wang X, Li Y et al.. “Minocycline as a therapeutic candidate in diabetic retinopathy: insights into pathophysiology and translational potential.” Experimental eye research (2026). PMID: 42320189 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  145. [145]

    Heier JS, Korobelnik JF, Brown DM et al.. “Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.” Ophthalmology (2016). PMID: 27651226 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  146. [146]

    Newman-Casey PA, Niziol LM, Elam AR et al.. “Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine Program: Impact on Vision, Follow-up, and Costs.” Ophthalmology (2025). PMID: 40311700 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Screening & Prevention
  147. [147]

    Bressler SB, Barve A, Ganapathi PC et al.. “Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.” JAMA ophthalmology (2024). PMID: 39264599 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  148. [148]

    Singh RP, Barakat MR, Ip MS et al.. “Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.” JAMA ophthalmology (2023). PMID: 37971723 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Prognosis & Natural History
  149. [149]

    Teo ZL, Tham YC, Yu M et al.. “Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis.” Ophthalmology (2021). PMID: 33940045 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  150. [150]

    Lee CT, Gayton EL, Beulens JW et al.. “Micronutrients and diabetic retinopathy a systematic review.” Ophthalmology (2009). PMID: 19900709 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  151. [151]

    Chia MA, Taylor JR, Stuart KV et al.. “Prevalence of Diabetic Retinopathy in Indigenous and Non-Indigenous Australians: A Systematic Review and Meta-analysis.” Ophthalmology (2022). PMID: 35931223 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  152. [152]

    Brown DM, Emanuelli A, Bandello F et al.. “KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.” American journal of ophthalmology (2022). PMID: 35038415 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  153. [153]

    Williams ZR, Morgenstern R, Erekat AN et al.. “Progression of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Occurs Early and Is Unassociated With Modifiable Risk Factors.” American journal of ophthalmology (2026). PMID: 41544737 ↗

    L3RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  154. [154]

    Prasad M, Agrón E, Vitale S et al.. “Diabetic Retinopathy Incidence, Progression, and Health-Related Quality of Life From the ACCORD Trial.” American journal of ophthalmology (2025). PMID: 40712766 ↗

    L3RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  155. [155]

    Shah J, Razavi P, Festok M et al.. “Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.” Ophthalmology (2026). PMID: 41577258 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
  156. [156]

    Sun D, Tseng VL, Yu F et al.. “Cardiovascular Risk and Eye Health: A Cohort Study of the Pooled Cohort Equations and Ocular Disease Incidence.” Ophthalmology (2025). PMID: 41475545 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors
  157. [157]

    Natividade GR, Spiazzi BF, Baumgarten MW et al.. “Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.” JAMA ophthalmology (2025). PMID: 40810985 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
  158. [158]

    Liu TYA, Ko S, Rosettie KL et al.. “Prevalence and Health Care Disparities of Retinal Conditions: A Meta-Analysis.” JAMA ophthalmology (2026). PMID: 41854587 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  159. [159]

    Lee SH, Tseng BY, Wu MC et al.. “Incidence and Progression of Diabetic Retinopathy After Cataract Surgery: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2024). PMID: 39179126 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  160. [160]

    Virk SA, Donaghue KC, Wong TY et al.. “Interventions for Diabetic Retinopathy in Type 1 Diabetes: Systematic Review and Meta-Analysis.” American journal of ophthalmology (2015). PMID: 26210869 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  161. [161]

    Chai YH, Zhang YP, Qiao YS et al.. “Association Between Diabetic Retinopathy, Brain Structural Abnormalities, and Cognitive Impairment for Accumulated Evidence in Observational Studies.” American journal of ophthalmology (2022). PMID: 35063409 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  162. [162]

    Yu CW, Park LJ, Pinto A et al.. “The Impact of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2021). PMID: 33428884 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  163. [163]

    Keeffe J, Taylor HR, Fotis K et al.. “Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990-2010.” The British journal of ophthalmology (2014). PMID: 24407561 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  164. [164]

    Naidoo K, Gichuhi S, Basáñez MG et al.. “Prevalence and causes of vision loss in sub-Saharan Africa: 1990-2010.” The British journal of ophthalmology (2014). PMID: 24568870 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  165. [165]

    Kai JY, Zhou M, Li DL et al.. “Smoking, dietary factors and major age-related eye disorders: an umbrella review of systematic reviews and meta-analyses.” The British journal of ophthalmology (2023). PMID: 36575624 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  166. [166]

    Nangia V, Jonas JB, George R et al.. “Prevalence and causes of blindness and vision impairment: magnitude, temporal trends and projections in South and Central Asia.” The British journal of ophthalmology (2018). PMID: 30409914 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  167. [167]

    Cheng CY, Wang N, Wong TY et al.. “Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections.” The British journal of ophthalmology (2019). PMID: 31462416 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  168. [168]

    Kahloun R, Khairallah M, Resnikoff S et al.. “Prevalence and causes of vision loss in North Africa and Middle East in 2015: magnitude, temporal trends and projections.” The British journal of ophthalmology (2018). PMID: 30209082 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  169. [169]

    Bourne RR, Jonas JB, Flaxman SR et al.. “Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010.” The British journal of ophthalmology (2014). PMID: 24665132 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  170. [170]

    Wang TW, Luo WT, Tu YK et al.. “Prospective validation of deep-learning algorithms for diabetic retinopathy screening: A systematic review and meta-analysis.” Survey of ophthalmology (2025). PMID: 41344407 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Screening & Prevention
  171. [171]

    Miele A, Govetto A, Fumagalli C et al.. “OCULAR HYPERTENSION AND GLAUCOMA FOLLOWING VITRECTOMY: A Systematic Review.” Retina (Philadelphia, Pa.) (2018). PMID: 28426628 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  172. [172]

    Simunovic MP, Maberley DA. “ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.” Retina (Philadelphia, Pa.) (2015). PMID: 26398553 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  173. [173]

    Testa F, Carreño E, van den Born LI et al.. “Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy.” Investigative ophthalmology & visual science (2024). PMID: 38884554 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Prognosis & Natural History
  174. [174]

    Balas M, Issa M, Popovic MM et al.. “ADAPTIVE OPTICS IMAGING IN DIABETIC RETINOPATHY: A Prospective Cohort Study.” Retina (Philadelphia, Pa.) (2024). PMID: 38478760 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification
  175. [175]

    Gilead N, Chong YJ, Yamaguchi TCN et al.. “Incidence of Visual Loss in Patients with Diabetic Macular Ischemia (DMI) A 1- year Prospective Study.” Retina (Philadelphia, Pa.) (2025). PMID: 40334126 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  176. [176]

    . “Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020.” Eye (London, England) (2024). PMID: 38937557 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup
  177. [177]

    Xu Y, Phu J, Aung HL et al.. “Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis.” Eye (London, England) (2023). PMID: 36922645 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
  178. [178]

    Haider S, Sadiq SN, Moore D et al.. “Prognostic prediction models for diabetic retinopathy progression: a systematic review.” Eye (London, England) (2019). PMID: 30651592 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations, Screening & Prevention
  179. [179]

    Trott M, Smith L, Veronese N et al.. “Eye disease and mortality, cognition, disease, and modifiable risk factors: an umbrella review of meta-analyses of observational studies.” Eye (London, England) (2021). PMID: 34272511 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
  180. [180]

    Ong AY, Kiire CA, Frise C et al.. “Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature.” Eye (London, England) (2023). PMID: 37980398 ↗

    L4SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  181. [181]

    Lundeen EA, Burke-Conte Z, Rein DB et al.. “Prevalence of Diabetic Retinopathy in the US in 2021.” JAMA ophthalmology (2023). PMID: 37318810 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  182. [182]

    Alsoudi AF, Wai KM, Koo E et al.. “Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy.” JAMA ophthalmology (2024). PMID: 39207799 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management
  183. [183]

    Pardue MT, Allen RS. “Neuroprotective strategies for retinal disease.” Progress in retinal and eye research (2018). PMID: 29481975 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Prognosis & Natural History
  184. [184]

    Bearse MA, Adams AJ, Han Y et al.. “A multifocal electroretinogram model predicting the development of diabetic retinopathy.” Progress in retinal and eye research (2006). PMID: 16949855 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  185. [185]

    Cunha-Vaz J, Ribeiro L, Lobo C. “Phenotypes and biomarkers of diabetic retinopathy.” Progress in retinal and eye research (2014). PMID: 24680929 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
  186. [186]

    Pan WW, Lin F, Fort PE. “The innate immune system in diabetic retinopathy.” Progress in retinal and eye research (2021). PMID: 33429059 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  187. [187]

    Ting DSW, Peng L, Varadarajan AV et al.. “Deep learning in ophthalmology: The technical and clinical considerations.” Progress in retinal and eye research (2019). PMID: 31048019 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations, Screening & Prevention
  188. [188]

    Jonas JB, Wang N, Yang D et al.. “Facts and myths of cerebrospinal fluid pressure for the physiology of the eye.” Progress in retinal and eye research (2015). PMID: 25619727 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  189. [189]

    Sunaga T, Maeda M, Saulle R et al.. “Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2024). PMID: 38829176 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  190. [190]

    Kataoka SY, Lois N, Kawano S et al.. “Fenofibrate for diabetic retinopathy.” The Cochrane database of systematic reviews (2023). PMID: 37310870 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  191. [191]

    Do DV, Han G, Abariga SA et al.. “Blood pressure control for diabetic retinopathy.” The Cochrane database of systematic reviews (2023). PMID: 36975019 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  192. [192]

    Martinez-Zapata MJ, Salvador I, Martí-Carvajal AJ et al.. “Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2023). PMID: 36939655 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management
  193. [193]

    Do DV, Wang X, Vedula SS et al.. “Blood pressure control for diabetic retinopathy.” The Cochrane database of systematic reviews (2015). PMID: 25637717 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  194. [194]

    Myint KT, Sahoo S, Thein AW et al.. “Laser therapy for retinopathy in sickle cell disease.” The Cochrane database of systematic reviews (2015). PMID: 26451693 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
  195. [195]

    Schwartz SG, Wang X, Chavis P et al.. “Vitamin A and fish oils for preventing the progression of retinitis pigmentosa.” The Cochrane database of systematic reviews (2020). PMID: 32573764 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  196. [196]

    Braithwaite T, Nanji AA, Lindsley K et al.. “Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.” The Cochrane database of systematic reviews (2014). PMID: 24788977 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  197. [197]

    Lakhani M, Kwan ATH, Mihalache A et al.. “Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.” American journal of ophthalmology (2025). PMID: 40383360 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  198. [198]

    Iyer SSR, Regan KA, Burnham JM et al.. “Surgical management of diabetic tractional retinal detachments.” Survey of ophthalmology (2019). PMID: 31077688 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  199. [199]

    Sadeghi E, Rahmanipour E, Valsecchi N et al.. “An update on ocular effects of antidiabetic medications.” Survey of ophthalmology (2025). PMID: 39855606 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  200. [200]

    Sivaprasad S, Gupta B, Crosby-Nwaobi R et al.. “Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective.” Survey of ophthalmology (2012). PMID: 22542913 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  201. [201]

    Tan R, Shahidzadeh A, Collazo A et al.. “The Association of Retinal Capillary Density and Retinal Thickness in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 41182028 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  202. [202]

    Shah J, Zhuang K, Kakihara S et al.. “Understanding How Low Luminance Visual Deficit Progresses With Advancing Diabetic Macular Ischemia and Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 41134256 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management
  203. [203]

    Wang Q, Wang YX, Wu SL et al.. “Ocular Axial Length and Diabetic Retinopathy: The Kailuan Eye Study.” Investigative ophthalmology & visual science (2019). PMID: 31469896 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  204. [204]

    Prasad R, Asare-Bediko B, Harbour A et al.. “Microbial Signatures in The Rodent Eyes With Retinal Dysfunction and Diabetic Retinopathy.” Investigative ophthalmology & visual science (2022). PMID: 34985498 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  205. [205]

    Chen Y, Xiong R, Zhang J et al.. “Ten-Year Change in Visual Function and Incidence of Visual Impairment in Highly Myopic Children and Adults.” Investigative ophthalmology & visual science (2025). PMID: 39745680 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  206. [206]

    Klein R, Klein BE. “The prevalence of age-related eye diseases and visual impairment in aging: current estimates.” Investigative ophthalmology & visual science (2013). PMID: 24335069 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  207. [207]

    Oncel D, Minaker S, Shepherd EA et al.. “RISK FACTORS FOR PROLIFERATIVE VITREORETINOPATHY IN A LARGE CLINICAL DATABASE.” Retina (Philadelphia, Pa.) (2025). PMID: 39752596 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
  208. [208]

    Borrelli E, Palmieri M, Viggiano P et al.. “PHOTORECEPTOR DAMAGE IN DIABETIC CHOROIDOPATHY.” Retina (Philadelphia, Pa.) (2020). PMID: 30986798 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  209. [209]

    Timtim E, Ji X, Bejjani R et al.. “Progression, Treatment, and Outcomes of Retinal Vascular Diseases in Pregnancy.” Retina (Philadelphia, Pa.) (2025). PMID: 40239168 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  210. [210]

    Talebi R, Fortes BH, Yu F et al.. “Real-world Associations Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Accounting for Longitudinal Glycemic Control.” Retina (Philadelphia, Pa.) (2025). PMID: 40334190 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History
  211. [211]

    Fu JJ, Applebaum SS, Granados A et al.. “Diabetic retinopathy treatment cascade and care continuum in the USA: a systematic review.” BMJ open (2026). PMID: 42270111 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Special Populations, Screening & Prevention
  212. [212]

    Jiang J, Guo W, Ding Z. “Risk factors for the occurrence and progression of diabetic retinopathy in children and adolescents: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42254634 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  213. [213]

    Chen KY, Chan HC, Chan CM. “Efficacy and safety of AAV-mediated gene therapy for choroideremia: a systematic review and meta-analysis.” EClinicalMedicine (2026). PMID: 42180403 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management
  214. [214]

    West SD, Turnbull C. “Obstructive sleep apnoea.” Eye (London, England) (2018). PMID: 29391572 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  215. [215]

    Irodi A, Zhu Z, Grzybowski A et al.. “The evolution of diabetic retinopathy screening.” Eye (London, England) (2025). PMID: 39910282 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  216. [216]

    Cheon S, Kim Y, Kang ES et al.. “Noncombustible Nicotine or Tobacco Product Use after Smoking Cessation and Major Vision-Impairing Diseases: A Nationwide Cohort Study.” American journal of ophthalmology (2026). PMID: 42288324 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
  217. [217]

    Wang Y, Zang B, Zhao J et al.. “Triglyceride-Glucose Indexes Are Predictive of Early and Severe Diabetic Retinal Microvascular Abnormalities: A Prospective Cohort Study.” Ophthalmology science (2026). PMID: 42199730 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
  218. [218]

    Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  219. [219]

    Aiello LP, Beck RW, Bressler NM et al.. “Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.” Ophthalmology (2011). PMID: 22136692 ↗

    L5GUIDELINECited in: Clinical Presentation, Prognosis & Natural History
  220. [220]

    Heier JS, Brown DM, Chong V et al.. “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.” Ophthalmology (2012). PMID: 23084240 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  221. [221]

    Holekamp NM, Campochiaro PA, Chang MA et al.. “Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.” Ophthalmology (2021). PMID: 34597713 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History, Special Populations, Screening & Prevention
  222. [222]

    Hillier RJ, Felfeli T, Berger AR et al.. “The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT).” Ophthalmology (2018). PMID: 30468761 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  223. [223]

    Sahni J, Patel SS, Dugel PU et al.. “Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.” Ophthalmology (2019). PMID: 30905643 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  224. [224]

    Lam BL, Pennesi ME, Kay CN et al.. “Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.” Ophthalmology (2024). PMID: 38423215 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management
  225. [225]

    Mitchell P, Wong TY. “Management paradigms for diabetic macular edema.” American journal of ophthalmology (2013). PMID: 24269850 ↗

    L5GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  226. [226]

    Brown DM, Wykoff CC, Boyer D et al.. “Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.” JAMA ophthalmology (2021). PMID: 34351414 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  227. [227]

    Lee WK, Iida T, Ogura Y et al.. “Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.” JAMA ophthalmology (2018). PMID: 29801063 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  228. [228]

    Gross JG, Glassman AR, Liu D et al.. “Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.” JAMA ophthalmology (2018). PMID: 30043039 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  229. [229]

    Maguire MJ, Laidlaw A, Hammond C et al.. “Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.” JAMA ophthalmology (2024). PMID: 39115867 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  230. [230]

    Pieramici DJ, Awh CC, Chang M et al.. “Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 40048178 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
  231. [231]

    Chhablani J, Sambhana S, Mathai A et al.. “Clinical efficacy of navigated panretinal photocoagulation in proliferative diabetic retinopathy.” American journal of ophthalmology (2015). PMID: 25703478 ↗

    L1RCTCited in: Clinical Presentation
  232. [232]

    Trejo Corona S, Villanueva Boone C, Ali AM et al.. “Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes.” Investigative ophthalmology & visual science (2023). PMID: 37351877 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  233. [233]

    Ng Yin Ling C, Seshasai S, Chee ML et al.. “Visual Impairment, Major Eye Diseases, and Mortality in a Multi-Ethnic Asian Population and a Meta-analysis of Prospective Studies.” American journal of ophthalmology (2021). PMID: 33965416 ↗

    L2SR_OBSCited in: Clinical Presentation
  234. [234]

    Zhao LQ, Zhu H, Zhao PQ et al.. “A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy.” The British journal of ophthalmology (2011). PMID: 21278146 ↗

    L2SR_OBSCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  235. [235]

    Murakami T, Kato S, Shigeeda T et al.. “Intensive treat-to-target statin therapy and severity of diabetic retinopathy complicated by hypercholesterolaemia.” Eye (London, England) (2020). PMID: 33106609 ↗

    L1RCTCited in: Clinical Presentation
  236. [236]

    Nanji K, Hatamnejad A, Grad J et al.. “Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review.” Survey of ophthalmology (2025). PMID: 40967513 ↗

    L2SR_OBSCited in: Clinical Presentation
  237. [237]

    Sarohia GS, Nanji K, Khan M et al.. “Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes.” Survey of ophthalmology (2022). PMID: 35476929 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis & Natural History
  238. [238]

    Jackson TL, Haller J, Blot KH et al.. “Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials.” Survey of ophthalmology (2021). PMID: 34480895 ↗

    L1SR_OBSCited in: Clinical Presentation, Prognosis & Natural History
  239. [239]

    Bowe T, Mahmoudzadeh R, Soares RR et al.. “CHARACTERISTICS OF PARTICIPANTS IN DIABETIC RETINOPATHY CLINICAL RESEARCH CLINICAL TRIALS WHO WERE LOST TO FOLLOW-UP.” Retina (Philadelphia, Pa.) (2024). PMID: 37603443 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation
  240. [240]

    Chaudhary V, Sarohia GS, Phillips MR et al.. “Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.” Eye (London, England) (2022). PMID: 36369263 ↗

    L1SR_OBSCited in: Clinical Presentation
  241. [241]

    Tomkins-Netzer O, Ismetova F, Bar A et al.. “Functional outcome of macular edema in different retinal disorders.” Progress in retinal and eye research (2015). PMID: 26014685 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  242. [242]

    Nowak-Sliwinska P, van den Bergh H, Sickenberg M et al.. “Photodynamic therapy for polypoidal choroidal vasculopathy.” Progress in retinal and eye research (2013). PMID: 24140257 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management
  243. [243]

    Kaur C, Foulds WS, Ling EA. “Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management.” Progress in retinal and eye research (2008). PMID: 18940262 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  244. [244]

    Yusuf AM, Bizrah M, Bunce C et al.. “Surgery for idiopathic epiretinal membrane.” The Cochrane database of systematic reviews (2021). PMID: 33760235 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  245. [245]

    Do DV, Gichuhi S, Vedula SS et al.. “Surgery for post-vitrectomy cataract.” The Cochrane database of systematic reviews (2013). PMID: 24357418 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  246. [246]

    Zhang HW, Zhang H, Grant SJ et al.. “Single herbal medicine for diabetic retinopathy.” The Cochrane database of systematic reviews (2018). PMID: 30566763 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  247. [247]

    Anguita R, Ferro Desideri L, Schwember P et al.. “Early Versus Delayed Vitrectomy for Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy.” American journal of ophthalmology (2024). PMID: 39471907 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
  248. [248]

    Pas JAAH, Valkenburg D, Li CHZ et al.. “The Visual Acuity Course in Stargardt Disease.” American journal of ophthalmology (2025). PMID: 40714056 ↗

    L2OTHERCited in: Clinical Presentation, Long-term & Definitive Management
  249. [249]

    Watanabe T, Keino H, Nakayama K et al.. “Clinical features of patients with diabetic anterior uveitis.” The British journal of ophthalmology (2018). PMID: 29563110 ↗

    L4OTHERCited in: Clinical Presentation
  250. [250]

    Wolf S, Chen Y, Li X et al.. “Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.” JAMA ophthalmology (2026). PMID: 42024409 ↗

    L1RCTCited in: Clinical Presentation, Prognosis & Natural History
  251. [251]

    Sinclair SH, Schwartz S. “Diabetic retinopathy: New concepts of screening, monitoring, and interventions.” Survey of ophthalmology (2024). PMID: 38964559 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Special Populations, Screening & Prevention
  252. [252]

    Chang JH, Garg NK, Lunde E et al.. “Corneal neovascularization: an anti-VEGF therapy review.” Survey of ophthalmology (2012). PMID: 22898649 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management
  253. [253]

    Chen XD, Gardner TW. “A critical review: Psychophysical assessments of diabetic retinopathy.” Survey of ophthalmology (2020). PMID: 32866468 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  254. [254]

    Kakihara S, Busza A, Yamaguchi TC et al.. “Posterior Retinal Ischemia Correlates With Vision in Patients With Diabetes.” Investigative ophthalmology & visual science (2025). PMID: 40455041 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification
  255. [255]

    Lu ZL, Zhao Y, Lesmes LA et al.. “Quantifying the Functional Relationship Between Visual Acuity and Contrast Sensitivity Function.” Investigative ophthalmology & visual science (2024). PMID: 39436371 ↗

    L4OTHERCited in: Clinical Presentation
  256. [256]

    Ramtohul P, Au A, Kunkler AL et al.. “CENTRAL BOUQUET HEMORRHAGE: Clinical and Multimodal Imaging Features.” Retina (Philadelphia, Pa.) (2024). PMID: 38109663 ↗

    L4OTHERCited in: Clinical Presentation, Long-term & Definitive Management
  257. [257]

    Lee T, Robbins CB, Wisely CE et al.. “CLINICAL CHARACTERISTICS AND VISUAL OUTCOMES IN ENDOPHTHALMITIS AFTER KERATOPROSTHESIS IMPLANTATION.” Retina (Philadelphia, Pa.) (2022). PMID: 34483314 ↗

    L4OTHERCited in: Clinical Presentation, Acute & Vision-Threatening Management
  258. [258]

    Rohowetz LJ, Shaheen A, Magraner M et al.. “SURGICAL OUTCOMES IN CONCURRENT SICKLE CELL AND DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2024). PMID: 39167577 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  259. [259]

    Shiraki A, Hara C, Akasaka H et al.. “Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind Study.” Geriatrics & gerontology international (2026). PMID: 42082179 ↗

    L2RCTCited in: Clinical Presentation, Prognosis & Natural History
  260. [260]

    Shao Y, Li H, Xu S et al.. “Efficacy of traditional Chinese medicine combined with Western drugs for the treatment of non-proliferative diabetic retinopathy: a meta-analysis.” Frontiers in medicine (2026). PMID: 42100286 ↗

    L1SR_OBSCited in: Clinical Presentation
  261. [261]

    Yang Q, Teo KYC, Hong Y et al.. “Flow and ischemic changes in retina and choroid across diabetic retinopathy spectrum: a SS-OCTA study.” Eye (London, England) (2025). PMID: 40016519 ↗

    L4OTHERCited in: Clinical Presentation
  262. [262]

    Bikbov MM, Kazakbaeva GM, Rakhimova EM et al.. “Mortality and ocular parameters and diseases.” Eye (London, England) (2025). PMID: 39856428 ↗

    L2OTHERCited in: Clinical Presentation
  263. [263]

    Liu Y, Huang J, Ao M et al.. “Real-world effect of vitrectomy combined with intravitreal conbercept for treatment of vitreous haemorrhage in proliferative diabetic retinopathy (QILIN I): a prospective cohort study.” The British journal of ophthalmology (2026). PMID: 41986090 ↗

    L2COHORTCited in: Clinical Presentation
  264. [264]

    Markan A, Agarwal A, Katoch D et al.. “Assessing the Role of Statins as an Adjunctive Anti-VEGF Therapy for Clinically Significant Macular Edema (CSME) in Type 2 Diabetes Mellitus.” Romanian journal of ophthalmology (2025). PMID: 41971206 ↗

    L1RCTCited in: Clinical Presentation
  265. [265]

    Zarbin M, Tabano D, Ahmed A et al.. “Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials.” Ophthalmology (2024). PMID: 38852921 ↗

    L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management, Prognosis & Natural History
  266. [266]

    Levin LA, Bhatti MT, Klier S et al.. “A Randomized Sham-Controlled Phase 2/3 Trial of QPI-1007 for Acute Nonarteritic Anterior Ischemic Optic Neuropathy.” Ophthalmology (2025). PMID: 40816607 ↗

    L1RCTCited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  267. [267]

    Zayed MG, Karsan W, Peto T et al.. “Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.” JAMA ophthalmology (2024). PMID: 38300578 ↗

    L2SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
  268. [268]

    Blinder KJ, Wykoff CC, Ferencz JR et al.. “IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION: Post Hoc Analysis of the MEAD Study.” Retina (Philadelphia, Pa.) (2025). PMID: 40712145 ↗

    L1RCTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History
  269. [269]

    Endo H, Kase S, Saito M et al.. “Choroidal Thickness in Diabetic Patients Without Diabetic Retinopathy: A Meta-analysis.” American journal of ophthalmology (2020). PMID: 32574782 ↗

    L2SR_OBSCited in: Diagnosis & Workup
  270. [270]

    Wang TW, Luo WT, Tu YK et al.. “Diagnostic Accuracy of EyeArt for Fundus-Based Detection of Diabetic Retinopathy: A Systematic Review and Meta-analysis.” American journal of ophthalmology (2025). PMID: 41052568 ↗

    L2SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  271. [271]

    Joseph S, Selvaraj J, Mani I et al.. “Diagnostic Accuracy of Artificial Intelligence-Based Automated Diabetic Retinopathy Screening in Real-World Settings: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2024). PMID: 38438095 ↗

    L2SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  272. [272]

    Shi L, Wu H, Dong J et al.. “Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis.” The British journal of ophthalmology (2015). PMID: 25563767 ↗

    L2SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  273. [273]

    Wong TY, Sun J, Kawasaki R et al.. “Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.” Ophthalmology (2018). PMID: 29776671 ↗

    L1REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management, Special Populations, Screening & Prevention
  274. [274]

    Xu S, Ruan Z, Wang Y et al.. “Establishment of Myopia Occurrence Prediction Model in Children without Myopia Using Cycloplegic Refraction and Prior Axial Length Change.” Ophthalmology (2025). PMID: 40516576 ↗

    L2OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
  275. [275]

    Varghese D, Abdelsalam D, Ibrahim S et al.. “Too much of a good thing.” Survey of ophthalmology (2026). PMID: 41520798 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup, Acute & Vision-Threatening Management
  276. [276]

    Cozzi M, Ziegler A, Fasler K et al.. “Sterile Intraocular Inflammation Associated With Faricimab.” JAMA ophthalmology (2024). PMID: 39388167 ↗

    L4OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
  277. [277]

    Tesfaye H, Paik JM, Roh M et al.. “Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.” JAMA ophthalmology (2025). PMID: 39636645 ↗

    L2OTHERCited in: Diagnosis & Workup
  278. [278]

    Spaide RF, Fujimoto JG, Waheed NK et al.. “Optical coherence tomography angiography.” Progress in retinal and eye research (2017). PMID: 29229445 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  279. [279]

    Waheed NK, Rosen RB, Jia Y et al.. “Optical coherence tomography angiography in diabetic retinopathy.” Progress in retinal and eye research (2023). PMID: 37499857 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
  280. [280]

    Savastano MC, Rizzo C, Fossataro C et al.. “Artificial intelligence in ophthalmology: Progress, challenges, and ethical implications.” Progress in retinal and eye research (2025). PMID: 40473198 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  281. [281]

    Jia Y, Hormel TT, Hwang TS et al.. “Widefield OCT angiography.” Progress in retinal and eye research (2025). PMID: 40517946 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  282. [282]

    Dysli C, Wolf S, Berezin MY et al.. “Fluorescence lifetime imaging ophthalmoscopy.” Progress in retinal and eye research (2017). PMID: 28673870 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management
  283. [283]

    Virgili G, Menchini F, Casazza G et al.. “Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.” The Cochrane database of systematic reviews (2015). PMID: 25564068 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  284. [284]

    Evans JR, Michelessi M, Virgili G. “Laser photocoagulation for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2014). PMID: 25420029 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  285. [285]

    Sarwar S, Clearfield E, Soliman MK et al.. “Aflibercept for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2016). PMID: 26857947 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  286. [286]

    Wang LZ, Cheung CY, Tapp RJ et al.. “Availability and variability in guidelines on diabetic retinopathy screening in Asian countries.” The British journal of ophthalmology (2017). PMID: 28292772 ↗

    L2REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
  287. [287]

    Gupta P, Gan ATL, Man REK et al.. “Association between diabetic retinopathy and incident cognitive impairment.” The British journal of ophthalmology (2019). PMID: 31645330 ↗

    L2OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Prognosis & Natural History
  288. [288]

    Lee PK, Ra H, Baek J. “Automated segmentation of ultra-widefield fluorescein angiography of diabetic retinopathy using deep learning.” The British journal of ophthalmology (2023). PMID: 36241374 ↗

    L3OTHERCited in: Diagnosis & Workup
  289. [289]

    Ghasemi Falavarjani K, Al-Sheikh M, Akil H et al.. “Image artefacts in swept-source optical coherence tomography angiography.” The British journal of ophthalmology (2016). PMID: 27439739 ↗

    L4OTHERCited in: Diagnosis & Workup
  290. [290]

    Stino H, Niederleithner M, Iby J et al.. “Detection of diabetic neovascularisation using single-capture 65°-widefield optical coherence tomography angiography.” The British journal of ophthalmology (2023). PMID: 36376062 ↗

    L3OTHERCited in: Diagnosis & Workup
  291. [291]

    Sultan MB, Starita C, Huang K. “Epidemiology, risk factors and management of paediatric diabetic retinopathy.” The British journal of ophthalmology (2012). PMID: 22241926 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
  292. [292]

    Parravano M, Cennamo G, Di Antonio L et al.. “Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers.” Survey of ophthalmology (2024). PMID: 38942124 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
  293. [293]

    Nouri H, Abtahi SH, Mazloumi M et al.. “Optical coherence tomography angiography in diabetic retinopathy: A major review.” Survey of ophthalmology (2024). PMID: 38521424 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  294. [294]

    McAnany JJ, Persidina OS, Park JC. “Clinical electroretinography in diabetic retinopathy: a review.” Survey of ophthalmology (2021). PMID: 34487740 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Prognosis & Natural History
  295. [295]

    Sambhav K, Grover S, Chalam KV. “The application of optical coherence tomography angiography in retinal diseases.” Survey of ophthalmology (2017). PMID: 28579550 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  296. [296]

    Pujari A, Bhaskaran K, Sharma P et al.. “Optical coherence tomography angiography in neuro-ophthalmology: Current clinical role and future perspectives.” Survey of ophthalmology (2020). PMID: 33157113 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  297. [297]

    Lai C, Su T, Cao J et al.. “Retinal Neurovascular Impairment in Full-Course Diabetic Retinopathy: The Guangdong Diabetic Retinopathy Multiple-Omics Study.” Investigative ophthalmology & visual science (2024). PMID: 39656471 ↗

    L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
  298. [298]

    Sadeghi E, Du K, Ajayi O et al.. “Three-Dimensional Choroidal Vessels Assessment in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40131298 ↗

    L3OTHERCited in: Diagnosis & Workup
  299. [299]

    Zhou L, Fan S, Lu H et al.. “Retinal and Choriocapillaris Thickness Changes in Spontaneously Diabetic Macaques.” Investigative ophthalmology & visual science (2025). PMID: 39908131 ↗

    L3OTHERCited in: Diagnosis & Workup
  300. [300]

    Wang J, Hormel T, Park DW et al.. “Quantifying Choriocapillaris Flow Deficits in Diabetic Retinopathy Using Projection-Resolved OCT Angiography.” Investigative ophthalmology & visual science (2025). PMID: 40905756 ↗

    L4OTHERCited in: Diagnosis & Workup
  301. [301]

    Liu H, Tang J, Lee CA et al.. “Metanx and early stages of diabetic retinopathy.” Investigative ophthalmology & visual science (2015). PMID: 25574044 ↗

    L2OTHERCited in: Diagnosis & Workup, Acute & Vision-Threatening Management
  302. [302]

    Kakihara S, Zhuang K, AbdelSalam M et al.. “The Importance of Matching Optical Coherence Tomography Angiography Metrics to Diabetic Retinopathy Severity for Detecting Progression.” Investigative ophthalmology & visual science (2025). PMID: 40838939 ↗

    L2OTHERCited in: Diagnosis & Workup
  303. [303]

    Spaide RF, Barquet LA. “RETINAL CAPILLARY MACROANEURYSMS.” Retina (Philadelphia, Pa.) (2019). PMID: 30489449 ↗

    L4OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  304. [304]

    Kesim C, Bektas SN, Kulali Z et al.. “HENLE FIBER LAYER MAPPING WITH DIRECTIONAL OPTICAL COHERENCE TOMOGRAPHY.” Retina (Philadelphia, Pa.) (2022). PMID: 35504010 ↗

    L4OTHERCited in: Diagnosis & Workup
  305. [305]

    Hwang TS, Jia Y, Gao SS et al.. “OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2015). PMID: 26308529 ↗

    L4OTHERCited in: Diagnosis & Workup
  306. [306]

    Tavares Ferreira J, Vicente A, Proença R et al.. “CHOROIDAL THICKNESS IN DIABETIC PATIENTS WITHOUT DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2018). PMID: 28267113 ↗

    L2OTHERCited in: Diagnosis & Workup
  307. [307]

    Le D, Son T, Lim JI et al.. “QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY REVEALS ROD PHOTORECEPTOR DEGENERATION in EARLY DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2022). PMID: 35316256 ↗

    L2OTHERCited in: Diagnosis & Workup
  308. [308]

    Lin CC, Cheng CK, Peng PH et al.. “REAL-WORLD PRACTICE OF ARTIFICIAL INTELLIGENCE DIAGNOSTIC SYSTEM FOR DIABETIC RETINOPATHY IN TAIWAN.” Retina (Philadelphia, Pa.) (2026). PMID: 41818422 ↗

    L3OTHERCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  309. [309]

    Rohart C, Le HM, Estrada-Walker J et al.. “LONG-TERM PROGNOSIS OF CHOROIDAL NEOVASCULARIZATION COMPLICATING ANGIOID STREAKS.” Retina (Philadelphia, Pa.) (2023). PMID: 36727798 ↗

    L3OTHERCited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
  310. [310]

    KamaliZonouzi S, Semnani F, Mahiny D et al.. “Retinal and choroidal optical coherence tomography findings in gestational diabetes mellitus: a systematic review and meta-analysis.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42270918 ↗

    L1SR_OBSCited in: Diagnosis & Workup
  311. [311]

    Mikhail D, Tao BK, Yu P et al.. “Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2026). PMID: 42219076 ↗

    L1SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  312. [312]

    Sun Z, Yang D, Tang Z et al.. “Optical coherence tomography angiography in diabetic retinopathy: an updated review.” Eye (London, England) (2020). PMID: 33099579 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup
  313. [313]

    Zhao X, Lin S, Lu L et al.. “Associations between sleep patterns and diabetic retinopathy: insights from cross-sectional and longitudinal evidence.” Eye (London, England) (2025). PMID: 41102556 ↗

    L2OTHERCited in: Diagnosis & Workup
  314. [314]

    Ong JX, Fawzi AA. “Perspectives on diabetic retinopathy from advanced retinal vascular imaging.” Eye (London, England) (2022). PMID: 34987198 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prognosis & Natural History
  315. [315]

    Hormenu T, Antiri EO, Ocansey S et al.. “Impact of physical activity on visual outcomes among persons with type 2 diabetes: A scoping review of randomized controlled trials.” Dialogues in health (2026). PMID: 42238251 ↗

    L2RCTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  316. [316]

    Xiang F, Li M, Li R et al.. “Macular microcirculation changes in incident type 2 diabetes without fundus Photography-Detectable diabetic Retinopathy: A 6-Year nested Case-Control study.” Diabetes research and clinical practice (2026). PMID: 42361856 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup
  317. [317]

    Li X, Yang L, Long H et al.. “Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.” Frontiers in medicine (2026). PMID: 42359082 ↗

    L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
  318. [318]

    Yan M, Zhang X, Li R et al.. “Automated Identification and Segmentation of Diabetic Macular Edema Subtypes Using Deep Learning.” Translational vision science & technology (2026). PMID: 42345636 ↗

    L4OTHERCited in: Diagnosis & Workup
  319. [319]

    Zheng C, Liu Y, Ling R et al.. “Widefield SS-OCTA-detected retinal vascular changes and their correlation with DME in diabetes.” Frontiers in endocrinology (2026). PMID: 42339092 ↗

    L2OTHERCited in: Diagnosis & Workup
  320. [320]

    He Q, Jiang H, Fang D et al.. “A Graph Neural Network-Based Multispectral-View Learning Model for Diabetic Macular Ischemia Detection From Color Fundus Photographs.” Translational vision science & technology (2026). PMID: 42334126 ↗

    L4OTHERCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
  321. [321]

    Ip MS, Zhang J, Ehrlich JS. “The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.” Ophthalmology (2017). PMID: 28284785 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  322. [322]

    Ehlers JP, Josic K, Aiello LP et al.. “Ultra-Widefield Fluorescein Angiographic Quantitative Leakage Parameters and Clinical Outcomes in Nonproliferative Diabetic Retinopathy.” JAMA ophthalmology (2026). PMID: 41609778 ↗

    L2RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
  323. [323]

    Sasako T, Ueki K, Miyoshi K et al.. “Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 41129145 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Special Populations, Screening & Prevention
  324. [324]

    Hou XW, Wang Y, Pan CW. “Metabolomics in Diabetic Retinopathy: A Systematic Review.” Investigative ophthalmology & visual science (2021). PMID: 34347011 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  325. [325]

    Feng Y, Zhu S, Skiadaresi E et al.. “PHACOEMULSIFICATION CATARACT SURGERY WITH PROPHYLACTIC INTRAVITREAL BEVACIZUMAB FOR PATIENTS WITH COEXISTING DIABETIC RETINOPATHY: A Meta-Analysis.” Retina (Philadelphia, Pa.) (2019). PMID: 29975344 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  326. [326]

    Xu H, Chen M, Forrester JV. “Para-inflammation in the aging retina.” Progress in retinal and eye research (2009). PMID: 19560552 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  327. [327]

    Moutray T, Evans JR, Lois N et al.. “Different lasers and techniques for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2018). PMID: 29543992 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  328. [328]

    Lopes de Jesus CC, Atallah AN, Valente O et al.. “Pentoxifylline for diabetic retinopathy.” The Cochrane database of systematic reviews (2008). PMID: 18425965 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  329. [329]

    Lin Z, Wen L, Wang Y et al.. “Incidence, progression and regression of diabetic retinopathy in a northeastern Chinese population.” The British journal of ophthalmology (2022). PMID: 35864776 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  330. [330]

    Cheung N, Chee ML, Klein R et al.. “Incidence and progression of diabetic retinopathy in a multi-ethnic US cohort: the Multi-Ethnic Study of Atherosclerosis.” The British journal of ophthalmology (2021). PMID: 33741582 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  331. [331]

    Benet D, Pellicer-Valero OJ. “Artificial intelligence: the unstoppable revolution in ophthalmology.” Survey of ophthalmology (2021). PMID: 33741420 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
  332. [332]

    Wang J, Yin Z, Yang J et al.. “BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40530920 ↗

    L5OTHERCited in: Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
  333. [333]

    Majidova SR. “Evaluation of Hypoxia and Microcirculation Factors in the Progression of Diabetic Retinopathy.” Investigative ophthalmology & visual science (2024). PMID: 38241030 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  334. [334]

    Anatriello A, Liguori V, Cagnotta C et al.. “Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.” Frontiers in pharmacology (2026). PMID: 42311413 ↗

    L2SR_OBSCited in: Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
  335. [335]

    Wykoff CC, Yu HJ, Avery RL et al.. “Retinal non-perfusion in diabetic retinopathy.” Eye (London, England) (2022). PMID: 35017700 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  336. [336]

    Sun JK, Wang PW, Taylor S et al.. “Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.” Ophthalmology (2018). PMID: 30419298 ↗

    L2RCTCited in: Acute & Vision-Threatening Management
  337. [337]

    Regillo C, Berger B, Brooks L et al.. “Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.” Ophthalmology (2023). PMID: 36870451 ↗

    L1RCTCited in: Acute & Vision-Threatening Management
  338. [338]

    Wykoff CC, Croft DE, Brown DM et al.. “Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.” Ophthalmology (2015). PMID: 26391465 ↗

    L1RCTCited in: Acute & Vision-Threatening Management
  339. [339]

    Yu HJ, Ehlers JP, Sevgi DD et al.. “Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.” American journal of ophthalmology (2021). PMID: 33529593 ↗

    L1RCTCited in: Acute & Vision-Threatening Management, Prognosis & Natural History
  340. [340]

    Ha A, Kim SH, Kang G et al.. “Association between Sight-Threatening Eye Diseases and Death by Suicide in South Korea: A Nationwide Population-based Cohort Study.” Ophthalmology (2023). PMID: 37001591 ↗

    L2COHORTCited in: Acute & Vision-Threatening Management
  341. [341]

    Widyaputri F, Rogers SL, Kandasamy R et al.. “Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes: A Systematic Review and Meta-analysis.” JAMA ophthalmology (2022). PMID: 35357410 ↗

    L2SR_OBSCited in: Acute & Vision-Threatening Management
  342. [342]

    Teo ZL, Tham YC, Yu M et al.. “Do we have enough ophthalmologists to manage vision-threatening diabetic retinopathy? A global perspective.” Eye (London, England) (2020). PMID: 31992863 ↗

    L2SR_OBSCited in: Acute & Vision-Threatening Management
  343. [343]

    Gurudas S, Frudd K, Maheshwari JJ et al.. “Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy.” JAMA ophthalmology (2022). PMID: 35511139 ↗

    L4OTHERCited in: Acute & Vision-Threatening Management
  344. [344]

    Meer E, Bavinger JC, Yu Y et al.. “Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.” JAMA ophthalmology (2022). PMID: 35389455 ↗

    L3OTHERCited in: Acute & Vision-Threatening Management
  345. [345]

    Sun Y, Li F, Liu Y et al.. “Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives.” Progress in retinal and eye research (2024). PMID: 38657834 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  346. [346]

    Stitt AW, O'Neill CL, O'Doherty MT et al.. “Vascular stem cells and ischaemic retinopathies.” Progress in retinal and eye research (2011). PMID: 21352947 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  347. [347]

    Kokavec J, Wu Z, Sherwin JC et al.. “Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters.” The Cochrane database of systematic reviews (2017). PMID: 28570745 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  348. [348]

    Lawrenson JG, Graham-Rowe E, Lorencatto F et al.. “Interventions to increase attendance for diabetic retinopathy screening.” The Cochrane database of systematic reviews (2018). PMID: 29333660 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
  349. [349]

    Grover D, Li TJ, Chong CC. “Intravitreal steroids for macular edema in diabetes.” The Cochrane database of systematic reviews (2008). PMID: 18254088 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management
  350. [350]

    Wong TY, Simó R, Mitchell P. “Fenofibrate - a potential systemic treatment for diabetic retinopathy?” American journal of ophthalmology (2012). PMID: 22709833 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  351. [351]

    Koh BMQR, Banu R, Nusinovici S et al.. “100 most-cited articles on diabetic retinopathy.” The British journal of ophthalmology (2020). PMID: 32855165 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
  352. [352]

    Ting DSJ, Foo VH, Yang LWY et al.. “Artificial intelligence for anterior segment diseases: Emerging applications in ophthalmology.” The British journal of ophthalmology (2020). PMID: 32532762 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  353. [353]

    Thomas RL, Dunstan FD, Luzio SD et al.. “Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service.” The British journal of ophthalmology (2014). PMID: 25091950 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  354. [354]

    Zatic T, Bendelic E, Paduca A et al.. “Rapid assessment of avoidable blindness and diabetic retinopathy in Republic of Moldova.” The British journal of ophthalmology (2014). PMID: 25550353 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  355. [355]

    Zhang G, Chen H, Chen W et al.. “Prevalence and risk factors for diabetic retinopathy in China: a multi-hospital-based cross-sectional study.” The British journal of ophthalmology (2017). PMID: 28855195 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  356. [356]

    Ooi KG, Khoo P, Vaclavik V et al.. “Statins in ophthalmology.” Survey of ophthalmology (2019). PMID: 30703407 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  357. [357]

    Errera MH, Kohly RP, da Cruz L. “Pregnancy-associated retinal diseases and their management.” Survey of ophthalmology (2013). PMID: 23410822 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  358. [358]

    Feizi S, Alemzadeh-Ansari M, Karimian F et al.. “Use of erythropoietin in ophthalmology: a review.” Survey of ophthalmology (2021). PMID: 34157346 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  359. [359]

    Khan R, Sharma A, Ravikumar R et al.. “Association Between Gut Microbial Abundance and Sight-Threatening Diabetic Retinopathy.” Investigative ophthalmology & visual science (2021). PMID: 34132747 ↗

    L3OTHERCited in: Acute & Vision-Threatening Management
  360. [360]

    Seddon JM. “Genetic and environmental underpinnings to age-related ocular diseases.” Investigative ophthalmology & visual science (2013). PMID: 24335064 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  361. [361]

    Grassi MA, Tikhomirov A, Ramalingam S et al.. “Replication analysis for severe diabetic retinopathy.” Investigative ophthalmology & visual science (2012). PMID: 22427569 ↗

    L3OTHERCited in: Acute & Vision-Threatening Management
  362. [362]

    Zhong X, Li H, Tan S et al.. “Initial Retinal Nerve Fiber Layer Loss and Risk of Diabetic Retinopathy Over a Four-Year Period.” Investigative ophthalmology & visual science (2024). PMID: 39365262 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  363. [363]

    Leclercq B, Mejlachowicz D, Zhu L et al.. “Differential Effect of Aldosterone or Mineralocorticoid Receptor Overexpression on Retinal Inflammation.” Investigative ophthalmology & visual science (2024). PMID: 39453673 ↗

    L5OTHERCited in: Acute & Vision-Threatening Management
  364. [364]

    Tayyari F, Khuu LA, Flanagan JG et al.. “Retinal Blood Flow and Retinal Blood Oxygen Saturation in Mild to Moderate Diabetic Retinopathy.” Investigative ophthalmology & visual science (2015). PMID: 26567792 ↗

    L4OTHERCited in: Acute & Vision-Threatening Management
  365. [365]

    Rajagopal R, McGill JB. “NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2024). PMID: 39151204 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  366. [366]

    Jaulim A, Ahmed B, Khanam T et al.. “Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature.” Retina (Philadelphia, Pa.) (2013). PMID: 23609064 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  367. [367]

    Moysidis SN, Vajzovic L, Gregori G et al.. “Acute retinal pigment epithelium detachments after photocoagulation.” Retina (Philadelphia, Pa.) (2014). PMID: 24013258 ↗

    L2OTHERCited in: Acute & Vision-Threatening Management
  368. [368]

    Luo C, Ruby A, Neuwelt M et al.. “Transvitreal fibrinoid pseudoendophthalmitis after diabetic vitrectomy.” Retina (Philadelphia, Pa.) (2013). PMID: 23609127 ↗

    L4OTHERCited in: Acute & Vision-Threatening Management
  369. [369]

    Wright AD, Dodson PM. “Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.” Eye (London, England) (2011). PMID: 21436845 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
  370. [370]

    Rajalakshmi R, Prathiba V, Arulmalar S et al.. “Review of retinal cameras for global coverage of diabetic retinopathy screening.” Eye (London, England) (2020). PMID: 33168977 ↗

    L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
  371. [371]

    Jin J, Ji F, Zhang J. “The Relationship between S100A9 Protein Levels and Diabetic Retinopathy among Type 2 Diabetes Patients: A Meta-Analysis.” Current protein & peptide science (2026). PMID: 42059242 ↗

    L1SR_OBSCited in: Acute & Vision-Threatening Management
  372. [372]

    Cui C, Li Y, Zhang Q. “The impact of diabetes mellitus and diabetic retinopathy on prognosis and complications after cataract surgery: Retrospective cohort study.” Medicine (2026). PMID: 42116355 ↗

    L2COHORTCited in: Acute & Vision-Threatening Management
  373. [373]

    Zhang Z, Zhang Q, Chen Y et al.. “Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping.” Alzheimer's research & therapy (2026). PMID: 42337644 ↗

    L4OTHERCited in: Acute & Vision-Threatening Management
  374. [374]

    Korobelnik JF, Do DV, Schmidt-Erfurth U et al.. “Intravitreal aflibercept for diabetic macular edema.” Ophthalmology (2014). PMID: 25012934 ↗

    L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  375. [375]

    Zhang ZH, Liu HY, Hernandez-Da Mota SE et al.. “Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.” American journal of ophthalmology (2013). PMID: 23791371 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  376. [376]

    Zhao XY, Xia S, Chen YX. “Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.” The British journal of ophthalmology (2017). PMID: 29246890 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  377. [377]

    Takkar B, Ketkar MR, Narula R et al.. “A Pilot Randomized Controlled Trial Evaluating Hemostasis With Fibrin Glue During Surgery for Proliferative Diabetic Retinopathy.” American journal of ophthalmology (2025). PMID: 39884371 ↗

    L1RCTCited in: Long-term & Definitive Management
  378. [378]

    Zhao S, Wu M, Zhong J et al.. “Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.” The British journal of ophthalmology (2026). PMID: 41448868 ↗

    L1RCTCited in: Long-term & Definitive Management
  379. [379]

    Zhang W, Cheng S, Gu X et al.. “Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial.” The British journal of ophthalmology (2025). PMID: 40122579 ↗

    L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
  380. [380]

    Chous AP, Richer SP, Gerson JD et al.. “The Diabetes Visual Function Supplement Study (DiVFuSS).” The British journal of ophthalmology (2015). PMID: 26089210 ↗

    L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  381. [381]

    Casswell EJ, Cro S, Cornelius VR et al.. “Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study.” The British journal of ophthalmology (2024). PMID: 36849205 ↗

    L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
  382. [382]

    Ockrim ZK, Sivaprasad S, Falk S et al.. “Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema.” The British journal of ophthalmology (2008). PMID: 18420749 ↗

    L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  383. [383]

    González VH, Giuliari GP, Banda RM et al.. “Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy.” The British journal of ophthalmology (2009). PMID: 19692371 ↗

    L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  384. [384]

    Khan MA, Hill L, Stoilov I et al.. “Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis.” JAMA ophthalmology (2025). PMID: 40208611 ↗

    L1SR_OBSCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  385. [385]

    Brown DM, Boyer DS, Csaky K et al.. “INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.” Retina (Philadelphia, Pa.) (2022). PMID: 35234673 ↗

    L1RCTCited in: Long-term & Definitive Management
  386. [386]

    Pak K, Yoon C, Sadda SR. “Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema.” Eye (London, England) (2026). PMID: 41904245 ↗

    L2RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
  387. [387]

    Narayanan SP, Rojas M, Suwanpradid J et al.. “Arginase in retinopathy.” Progress in retinal and eye research (2013). PMID: 23830845 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  388. [388]

    Purdy R, John M, Bray A et al.. “Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy.” Progress in retinal and eye research (2025). PMID: 40090458 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  389. [389]

    Penn JS, Madan A, Caldwell RB et al.. “Vascular endothelial growth factor in eye disease.” Progress in retinal and eye research (2008). PMID: 18653375 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Special Populations, Screening & Prevention
  390. [390]

    Laíns I, Gantner M, Murinello S et al.. “Metabolomics in the study of retinal health and disease.” Progress in retinal and eye research (2018). PMID: 30423446 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  391. [391]

    Grossniklaus HE, Kang SJ, Berglin L. “Animal models of choroidal and retinal neovascularization.” Progress in retinal and eye research (2010). PMID: 20488255 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  392. [392]

    Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I et al.. “Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2014). PMID: 25418485 ↗

    L1SR_OBSCited in: Long-term & Definitive Management
  393. [393]

    Viggiano P, Carra A, Bruno G et al.. “Microaneurysm Reflectivity as a Prognostic Biomarker for Intravitreal Treatment Response in Diabetic Retinopathy.” American journal of ophthalmology (2026). PMID: 41617122 ↗

    L2OTHERCited in: Long-term & Definitive Management
  394. [394]

    Sasongko MB, Wardhana FS, Febryanto GA et al.. “The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025.” The British journal of ophthalmology (2019). PMID: 31285276 ↗

    L2OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  395. [395]

    Iacono P, Parodi MB, Scaramuzzi M et al.. “Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant.” The British journal of ophthalmology (2016). PMID: 27625164 ↗

    L4OTHERCited in: Long-term & Definitive Management
  396. [396]

    Manousaridis K, Talks J. “Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?” The British journal of ophthalmology (2012). PMID: 22250209 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  397. [397]

    Tan Y, Fukutomi A, Sun MT et al.. “Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.” Survey of ophthalmology (2021). PMID: 33705807 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  398. [398]

    Sivaprasad S, Elagouz M, McHugh D et al.. “Micropulsed diode laser therapy: evolution and clinical applications.” Survey of ophthalmology (2010). PMID: 20850854 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  399. [399]

    Stefánsson E. “Ocular oxygenation and the treatment of diabetic retinopathy.” Survey of ophthalmology (2006). PMID: 16818083 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  400. [400]

    Lally DR, Shah CP, Heier JS. “Vascular endothelial growth factor and diabetic macular edema.” Survey of ophthalmology (2016). PMID: 27045225 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  401. [401]

    Bressler NM, Kaiser PK, Do DV et al.. “Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.” Survey of ophthalmology (2024). PMID: 38521423 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  402. [402]

    Wei X, Balne PK, Meissner KE et al.. “Assessment of flow dynamics in retinal and choroidal microcirculation.” Survey of ophthalmology (2018). PMID: 29577954 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  403. [403]

    Piroozmand S, Latifi-Navid H, Soheili ZS et al.. “Suboptimal Responses to Anti-VEGF in Retinal Neurovascular Diseases: Linking Aging and Alternative Angioinflammatory Pathways.” Investigative ophthalmology & visual science (2026). PMID: 42080790 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  404. [404]

    Calton MA, Croze RH, Burns C et al.. “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.” Investigative ophthalmology & visual science (2024). PMID: 39620832 ↗

    L5OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  405. [405]

    Park SS. “Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion.” Investigative ophthalmology & visual science (2016). PMID: 27116667 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  406. [406]

    Skeie JM, Nishimura DY, Wang CL et al.. “Mitophagy: An Emerging Target in Ocular Pathology.” Investigative ophthalmology & visual science (2021). PMID: 33724294 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  407. [407]

    Pauleikhoff L, Boneva S, Boeck M et al.. “Transcriptional Comparison of Human and Murine Retinal Neovascularization.” Investigative ophthalmology & visual science (2023). PMID: 38153746 ↗

    L5OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  408. [408]

    Viggiano P, Miere A, Borrelli E et al.. “The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD.” Investigative ophthalmology & visual science (2023). PMID: 37988106 ↗

    L4OTHERCited in: Long-term & Definitive Management
  409. [409]

    Boscia G, Bacherini D, Vujosevic S et al.. “Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD.” Investigative ophthalmology & visual science (2024). PMID: 39093297 ↗

    L3OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History
  410. [410]

    Peyman GA, Lad EM, Moshfeghi DM. “Intravitreal injection of therapeutic agents.” Retina (Philadelphia, Pa.) (2009). PMID: 19584648 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  411. [411]

    Su T, Lai C, Du Z et al.. “RETINAL PHOTORECEPTORS AND ARTERIOLES ALTERATIONS DETECTED USING ADAPTIVE OPTICS SCANNING LASER OPHTHALMOSCOPY IN DIABETES AND DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2026). PMID: 40865080 ↗

    L4OTHERCited in: Long-term & Definitive Management
  412. [412]

    Osaadon P, Fagan XJ, Lifshitz T et al.. “A review of anti-VEGF agents for proliferative diabetic retinopathy.” Eye (London, England) (2014). PMID: 24525867 ↗

    L2REVIEW_NARRATIVECited in: Long-term & Definitive Management
  413. [413]

    Chatziralli I, Touhami S, Cicinelli MV et al.. “Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.” Eye (London, England) (2021). PMID: 34408316 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  414. [414]

    Dinah C, Dodds M, Lotery A et al.. “Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study.” Eye (London, England) (2025). PMID: 41238745 ↗

    L2OTHERCited in: Long-term & Definitive Management
  415. [415]

    Hari T, Elsherbiny S. “Bariatric surgery-what the ophthalmologist needs to know.” Eye (London, England) (2021). PMID: 34675393 ↗

    L2REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
  416. [416]

    Falavarjani KG, Nguyen QD. “Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.” Eye (London, England) (2013). PMID: 23722722 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  417. [417]

    Chong V. “Ranibizumab for the treatment of wet AMD: a summary of real-world studies.” Eye (London, England) (2015). PMID: 26634711 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  418. [418]

    Wang Y, Zhang Q, Pan H et al.. “Chain mediating effect of social support and psychological resilience between quality of discharge teaching and readiness for hospital discharge in patients with diabetic retinopathy surgery.” Frontiers in public health (2026). PMID: 42359153 ↗

    L4OTHERCited in: Long-term & Definitive Management
  419. [419]

    Heck K, Hatz K, Cattaneo M et al.. “Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.” Ophthalmology and therapy (2026). PMID: 42334530 ↗

    L2OTHERCited in: Long-term & Definitive Management
  420. [420]

    Lee JY, Joo CK, Shawl AI et al.. “Local and Systemic Immunologic Profiles Differentiate Accepted and Rejected Islet Grafts in a Rat Anterior Chamber Model.” Journal of immunology research (2026). PMID: 42324809 ↗

    L5OTHERCited in: Long-term & Definitive Management
  421. [421]

    Tang J, Sun Y, Jin E et al.. “A two-step approach for suprachoroidal delivery of dexamethasone implant using a custom-made injector.” International journal of retina and vitreous (2026). PMID: 42316264 ↗

    L4OTHERCited in: Long-term & Definitive Management
  422. [422]

    Luu B, van Dijk EHC, Hein M et al.. “Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy.” Survey of ophthalmology (2026). PMID: 42314860 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  423. [423]

    Xia D, Li W, Xie J et al.. “Supramolecular peptide hydrogels for the treatment of ocular diseases: from tissue replacements to drug delivery systems.” Journal of materials chemistry. B (2026). PMID: 42300220 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
  424. [424]

    Zhang S, Ran A, Zhou J et al.. “An AI-Based OCT System to Detect Diabetic Macular Edema: A Prospective Validation and Noninferiority Randomized Clinical Trial.” JAMA (2026). PMID: 42295755 ↗

    L1OTHERCited in: Long-term & Definitive Management
  425. [425]

    Su L, Ren X, Wei H et al.. “INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2016). PMID: 26630313 ↗

    L1RCTCited in: Surgical, Laser & Procedural Considerations
  426. [426]

    Chen GH, Tzekov R, Mao SH et al.. “Intravitreal conbercept as an adjuvant in vitrectomy for proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.” Eye (London, England) (2021). PMID: 33824510 ↗

    L1SR_MA_RCTCited in: Surgical, Laser & Procedural Considerations
  427. [427]

    Kim LN, Mehta H, Barthelmes D et al.. “METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2016). PMID: 27388744 ↗

    L2SR_OBSCited in: Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  428. [428]

    Cheung N, Wong TY. “Diabetic retinopathy and systemic vascular complications.” Progress in retinal and eye research (2007). PMID: 18249026 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  429. [429]

    Roy S, Jiang JX, Li AF et al.. “Connexin channel and its role in diabetic retinopathy.” Progress in retinal and eye research (2017). PMID: 28602949 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  430. [430]

    Padovani-Claudio DA, Ramos CJ, Capozzi ME et al.. “Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis.” Progress in retinal and eye research (2023). PMID: 37028118 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  431. [431]

    Mastropasqua R, Toto L, Cipollone F et al.. “Role of microRNAs in the modulation of diabetic retinopathy.” Progress in retinal and eye research (2014). PMID: 25128741 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  432. [432]

    Carlà MM, Giannuzzi F, Boselli F et al.. “The applications of viscoelastic agents in vitreoretinal surgery.” Survey of ophthalmology (2025). PMID: 39952440 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations, Prognosis & Natural History
  433. [433]

    Lai D, Wu Y, Shao C et al.. “The Role of Müller Cells in Diabetic Macular Edema.” Investigative ophthalmology & visual science (2023). PMID: 37418272 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  434. [434]

    Thakur PS, Aggarwal D, Takkar B et al.. “Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2022). PMID: 35877085 ↗

    L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
  435. [435]

    Yan B, Qiu J, Yang Y et al.. “Exosomal miRNA Profiling in Liquid Biopsy of Vitreous in Proliferative Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40637511 ↗

    L3OTHERCited in: Surgical, Laser & Procedural Considerations
  436. [436]

    Murphy DC, Al-Zubaidy M, Lois N et al.. “The Effect of Macular Hole Duration on Surgical Outcomes: An Individual Participant Data Study of Randomized Controlled Trials.” Ophthalmology (2022). PMID: 36058348 ↗

    L1SR_MA_RCTCited in: Prognosis & Natural History
  437. [437]

    Sadda S, Sarraf D, Khanani AM et al.. “Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.” The British journal of ophthalmology (2024). PMID: 37669850 ↗

    L1RCTCited in: Prognosis & Natural History
  438. [438]

    Gale R, Scanlon PH, Evans M et al.. “Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.” Eye (London, England) (2017). PMID: 28490797 ↗

    L5GUIDELINECited in: Prognosis & Natural History
  439. [439]

    Wykoff CC, Ou WC, Khurana RN et al.. “Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.” The British journal of ophthalmology (2017). PMID: 28814412 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis & Natural History
  440. [440]

    Khan Z, Gaidhane AM, Singh M et al.. “Diagnostic Accuracy of IDX-DR for Detecting Diabetic Retinopathy: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2025). PMID: 39986640 ↗

    L2SR_OBSCited in: Prognosis & Natural History, Special Populations, Screening & Prevention
  441. [441]

    Zhang C, Xia Z, Mao W et al.. “Optical coherence tomography angiogropahy changes in patients with diabetic retinopathy treated with panretinal photocoagulation: A systematic review and meta-analysis.” Survey of ophthalmology (2025). PMID: 41207511 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  442. [442]

    Zhang SX, Wang JJ, Starr CR et al.. “The endoplasmic reticulum: Homeostasis and crosstalk in retinal health and disease.” Progress in retinal and eye research (2023). PMID: 38092262 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  443. [443]

    Nawaz IM, Rezzola S, Cancarini A et al.. “Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications.” Progress in retinal and eye research (2019). PMID: 30951889 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  444. [444]

    Zaluski J, Bassetto M, Kiser PD et al.. “Advances and therapeutic opportunities in visual cycle modulation.” Progress in retinal and eye research (2025). PMID: 40280538 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  445. [445]

    Cundy O, Lange CA, Bunce C et al.. “Face-down positioning or posturing after macular hole surgery.” The Cochrane database of systematic reviews (2023). PMID: 37987517 ↗

    L1SR_OBSCited in: Prognosis & Natural History
  446. [446]

    Lam FC, Chia SN, Lee RM. “Macular grid laser photocoagulation for branch retinal vein occlusion.” The Cochrane database of systematic reviews (2015). PMID: 25961835 ↗

    L1SR_OBSCited in: Prognosis & Natural History
  447. [447]

    Lu S, Lin Y, Lin L et al.. “Efficacy and safety of different anti-VEGF agents combined with pars plana vitrectomy in proliferative diabetic retinopathy: a systematic review and network meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 41958881 ↗

    L1SR_MA_RCTCited in: Prognosis & Natural History
  448. [448]

    Jiang W, Wang J, Li J et al.. “Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial.” Frontiers in endocrinology (2026). PMID: 41928879 ↗

    L2RCTCited in: Prognosis & Natural History
  449. [449]

    Nakashima H, Ikeda S, Shinohara K et al.. “Prognostic Value of the Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Ratio for Cardiovascular Events in Statin-Treated Type 2 Diabetes With Diabetic Retinopathy Without Prior Cardiovascular Disease.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41922276 ↗

    L2RCTCited in: Prognosis & Natural History
  450. [450]

    Khayat M, Williams M, Lois N. “Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion.” Survey of ophthalmology (2018). PMID: 29705175 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  451. [451]

    Chang RC, Shi L, Huang CC et al.. “High-Fat Diet-Induced Retinal Dysfunction.” Investigative ophthalmology & visual science (2015). PMID: 25788653 ↗

    L5OTHERCited in: Prognosis & Natural History, Special Populations, Screening & Prevention
  452. [452]

    Tang VTS, Symons RCA, Fourlanos S et al.. “Contrast Increment and Decrement Processing in Individuals With and Without Diabetes.” Investigative ophthalmology & visual science (2023). PMID: 37083950 ↗

    L3OTHERCited in: Prognosis & Natural History
  453. [453]

    Fragiotta S, Costanzo E, Picconi F et al.. “Progression Biomarkers of Microvascular and Photoreceptor Changes Upon Long-Term Evaluation in Type 1 Diabetes.” Investigative ophthalmology & visual science (2023). PMID: 37227747 ↗

    L2OTHERCited in: Prognosis & Natural History
  454. [454]

    Torres-Villaros H, Timoumi R, Fajnkuchen F et al.. “MACULAR THICKNESS FLUCTUATIONS AND VISUAL ACUITY OUTCOMES AFTER INTRAVITREAL DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA.” Retina (Philadelphia, Pa.) (2024). PMID: 39208410 ↗

    L4OTHERCited in: Prognosis & Natural History
  455. [455]

    Sivaprasad S, Arden G. “Spare the rods and spoil the retina: revisited.” Eye (London, England) (2015). PMID: 26656085 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  456. [456]

    Hark LA, Katz LJ, Myers JS et al.. “Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Methods and Screening Results.” American journal of ophthalmology (2017). PMID: 28673747 ↗

    L1RCTCited in: Special Populations, Screening & Prevention
  457. [457]

    Assi L, Chamseddine F, Ibrahim P et al.. “A Global Assessment of Eye Health and Quality of Life: A Systematic Review of Systematic Reviews.” JAMA ophthalmology (2021). PMID: 33576772 ↗

    L2SR_OBSCited in: Special Populations, Screening & Prevention
  458. [458]

    Rahmati M, Smith L, Boyer L et al.. “Factors Affecting Global Adherence for the Uptake of Diabetic Retinopathy Screening: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2024). PMID: 39094991 ↗

    L2SR_OBSCited in: Special Populations, Screening & Prevention
  459. [459]

    Sharafeldin N, Kawaguchi A, Sundaram A et al.. “Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults.” The British journal of ophthalmology (2018). PMID: 29680803 ↗

    L5SR_OBSCited in: Special Populations, Screening & Prevention
  460. [460]

    Butt AB, Ahmed F, Mihalache A et al.. “SOCIODEMOGRAPHIC FACTORS AS PREDICTORS OF DIABETIC RETINOPATHY SCREENING: A Systematic Review.” Retina (Philadelphia, Pa.) (2026). PMID: 41874556 ↗

    L2SR_OBSCited in: Special Populations, Screening & Prevention
  461. [461]

    Rathi S, Tsui E, Mehta N et al.. “The Current State of Teleophthalmology in the United States.” Ophthalmology (2017). PMID: 28647202 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
  462. [462]

    Thomas CG, Channa R, Prichett L et al.. “Racial/Ethnic Disparities and Barriers to Diabetic Retinopathy Screening in Youths.” JAMA ophthalmology (2021). PMID: 34042939 ↗

    L3OTHERCited in: Special Populations, Screening & Prevention
  463. [463]

    Li JO, Liu H, Ting DSJ et al.. “Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective.” Progress in retinal and eye research (2020). PMID: 32898686 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
  464. [464]

    Kador PF, Wyman M, Oates PJ. “Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).” Progress in retinal and eye research (2016). PMID: 27102270 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
  465. [465]

    Froger N, Moutsimilli L, Cadetti L et al.. “Taurine: the comeback of a neutraceutical in the prevention of retinal degenerations.” Progress in retinal and eye research (2014). PMID: 24721186 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
  466. [466]

    Smith JM, Steel DH. “Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2011). PMID: 21563165 ↗

    L1SR_OBSCited in: Special Populations, Screening & Prevention
  467. [467]

    Smith JM, Steel DH. “Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2015). PMID: 26250103 ↗

    L1SR_OBSCited in: Special Populations, Screening & Prevention
  468. [468]

    Nwanyanwu K, Andoh J, Chen E et al.. “Social Determinants Associated with Diabetic Retinopathy Awareness: National Health and Nutrition Examination Survey (2005-2008).” American journal of ophthalmology (2025). PMID: 40550446 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention
  469. [469]

    Yang Z, Zhang J, Zheng Y. “Associations Between Life's Essential 8 and Major Ocular Diseases in the American Middle-Aged and Elderly Population.” American journal of ophthalmology (2024). PMID: 39089359 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention
  470. [470]

    Kakihara S, Zhuang K, Fawzi AA. “Macular Deep Capillary Plexus Ischemia as a Biomarker for Identifying Referable Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 41251524 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention
  471. [471]

    Hussain R, Czanner G, Taktak A et al.. “MORTALITY OF PATIENTS WITH UVEAL MELANOMA DETECTED BY DIABETIC RETINOPATHY SCREENING.” Retina (Philadelphia, Pa.) (2020). PMID: 32032260 ↗

    L3OTHERCited in: Special Populations, Screening & Prevention
  472. [472]

    He X, Deng X, Lin Z et al.. “SCREENING AND MONITORING OF DIABETIC RETINOPATHY IN COMMUNITY CARE: The Effectiveness of Single-Field Versus Multifield Fundus Photography.” Retina (Philadelphia, Pa.) (2025). PMID: 39437367 ↗

    L2OTHERCited in: Special Populations, Screening & Prevention
  473. [473]

    Arruabarrena C, Rodríguez-Miguel A, Allendes G et al.. “EVALUATION OF THE INCLUSION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN A TELEMEDICINE DIABETIC RETINOPATHY SCREENING PROGRAM: A Real Clinical Practice.” Retina (Philadelphia, Pa.) (2023). PMID: 37155959 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention
  474. [474]

    Aiello LP, Jacoba CMP, Ashraf M et al.. “INTEGRATING MACULAR OPTICAL COHERENCE TOMOGRAPHY WITH ULTRAWIDE-FIELD IMAGING IN A DIABETIC RETINOPATHY TELEMEDICINE PROGRAM USING A SINGLE DEVICE.” Retina (Philadelphia, Pa.) (2023). PMID: 37871272 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention
  475. [475]

    Wei C, Zhang L, Chen C et al.. “Quantifying the Economic Value of AI-Assisted Diabetic Retinopathy Screening: A Meta-Analysis Using the Incremental Net Benefit Framework.” Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2026). PMID: 42336317 ↗

    L2SR_OBSCited in: Special Populations, Screening & Prevention
  476. [476]

    Kumari S, Venkatesh P, Tandon N et al.. “Selfie fundus imaging for diabetic retinopathy screening.” Eye (London, England) (2021). PMID: 34642496 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention
  477. [477]

    Grzybowski A, Brona P, Lim G et al.. “Artificial intelligence for diabetic retinopathy screening: a review.” Eye (London, England) (2019). PMID: 31488886 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
  478. [478]

    Yalaev BI, Khusainova RI, Minniakhmetov IR et al.. “Genetic Determinants of Microvascular Complications of Type 1 Diabetes Mellitus: New Data from a Replication Study.” Biomedicines (2026). PMID: 42351627 ↗

    L3OTHERCited in: Special Populations, Screening & Prevention
  479. [479]

    Samayamanthula S, Williams J, Markowski A et al.. “Blood Pressure Assessment in Ophthalmology Clinics for Patients With Diabetes.” JAMA ophthalmology (2026). PMID: 42348192 ↗

    L4OTHERCited in: Special Populations, Screening & Prevention

Revision History

All updates applied to this page

Loading revisions…